text stringlengths 985 288k | stock_price_percentage_change stringclasses 114 values | symbol stringclasses 503 values | period stringclasses 308 values |
|---|---|---|---|
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2019-12-28 to 2020-01-03
[Next Week]: 2020-01-03 to 2020-01-10
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-01-03:
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
Quarter ending 2019-01-31 (FY 2019 Q1, currency: USD):
- Profitability: net margin 39.3%, operating margin 19.5%.
- Valuation: P/E 12.0x, P/B 4.8x, P/S 18.8x, P/FCF 139.0x.
- Balance sheet & liquidity: debt/equity 0.36, debt/assets 0.20, current ratio 3.39, quick ratio 2.79, cash ratio 1.88.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 16.6%, FCF / OCF 81.7%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
- 2019-02-20: EPS actual 0.76 / estimate 0.73 / surprise +0.03 | revenue actual 1284000000 / estimate 1175387668 / surprise +108612332
From 2019-12-28 to 2020-01-03, A's stock price decreased from 85.95 to 84.57. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 4 | A | 2019-12-28 to 2020-01-10 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-01-04 to 2020-01-10
[Next Week]: 2020-01-10 to 2020-01-17
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-01-10:
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
Quarter ending 2019-01-31 (FY 2019 Q1, currency: USD):
- Profitability: net margin 39.3%, operating margin 19.5%.
- Valuation: P/E 12.0x, P/B 4.8x, P/S 18.8x, P/FCF 139.0x.
- Balance sheet & liquidity: debt/equity 0.36, debt/assets 0.20, current ratio 3.39, quick ratio 2.79, cash ratio 1.88.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 16.6%, FCF / OCF 81.7%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
- 2019-02-20: EPS actual 0.76 / estimate 0.73 / surprise +0.03 | revenue actual 1284000000 / estimate 1175387668 / surprise +108612332
From 2020-01-04 to 2020-01-10, A's stock price increased from 84.82 to 87.59. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 3 | A | 2020-01-04 to 2020-01-17 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-01-11 to 2020-01-17
[Next Week]: 2020-01-17 to 2020-01-24
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-01-17:
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
Quarter ending 2019-01-31 (FY 2019 Q1, currency: USD):
- Profitability: net margin 39.3%, operating margin 19.5%.
- Valuation: P/E 12.0x, P/B 4.8x, P/S 18.8x, P/FCF 139.0x.
- Balance sheet & liquidity: debt/equity 0.36, debt/assets 0.20, current ratio 3.39, quick ratio 2.79, cash ratio 1.88.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 16.6%, FCF / OCF 81.7%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
- 2019-02-20: EPS actual 0.76 / estimate 0.73 / surprise +0.03 | revenue actual 1284000000 / estimate 1175387668 / surprise +108612332
From 2020-01-11 to 2020-01-17, A's stock price increased from 87.46 to 90.12. News during this period are listed below:
[News]:
No relevant company news reported during this week. | -2 | A | 2020-01-11 to 2020-01-24 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-01-18 to 2020-01-24
[Next Week]: 2020-01-24 to 2020-01-31
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-01-24:
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
Quarter ending 2019-01-31 (FY 2019 Q1, currency: USD):
- Profitability: net margin 39.3%, operating margin 19.5%.
- Valuation: P/E 12.0x, P/B 4.8x, P/S 18.8x, P/FCF 139.0x.
- Balance sheet & liquidity: debt/equity 0.36, debt/assets 0.20, current ratio 3.39, quick ratio 2.79, cash ratio 1.88.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 16.6%, FCF / OCF 81.7%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
- 2019-02-20: EPS actual 0.76 / estimate 0.73 / surprise +0.03 | revenue actual 1284000000 / estimate 1175387668 / surprise +108612332
From 2020-01-18 to 2020-01-24, A's stock price decreased from 89.61 to 88.26. News during this period are listed below:
[News]:
No relevant company news reported during this week. | -6 | A | 2020-01-18 to 2020-01-31 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-01-25 to 2020-01-31
[Next Week]: 2020-01-31 to 2020-02-07
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-01-31:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
- 2019-02-20: EPS actual 0.76 / estimate 0.73 / surprise +0.03 | revenue actual 1284000000 / estimate 1175387668 / surprise +108612332
From 2020-01-25 to 2020-01-31, A's stock price decreased from 86.56 to 82.56. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 1 | A | 2020-01-25 to 2020-02-07 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-02-01 to 2020-02-07
[Next Week]: 2020-02-07 to 2020-02-14
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-02-07:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
- 2019-02-20: EPS actual 0.76 / estimate 0.73 / surprise +0.03 | revenue actual 1284000000 / estimate 1175387668 / surprise +108612332
From 2020-02-01 to 2020-02-07, A's stock price increased from 82.15 to 83.17. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 3 | A | 2020-02-01 to 2020-02-14 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-02-08 to 2020-02-14
[Next Week]: 2020-02-14 to 2020-02-21
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-02-14:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
- 2019-02-20: EPS actual 0.76 / estimate 0.73 / surprise +0.03 | revenue actual 1284000000 / estimate 1175387668 / surprise +108612332
From 2020-02-08 to 2020-02-14, A's stock price increased from 84.43 to 85.82. News during this period are listed below:
[News]:
No relevant company news reported during this week. | -1 | A | 2020-02-08 to 2020-02-21 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-02-15 to 2020-02-21
[Next Week]: 2020-02-21 to 2020-02-28
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-02-21:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-02-15 to 2020-02-21, A's stock price increased from 84.79 to 85.07. News during this period are listed below:
[News]:
No relevant company news reported during this week. | -9 | A | 2020-02-15 to 2020-02-28 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-02-22 to 2020-02-28
[Next Week]: 2020-02-28 to 2020-03-06
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-02-28:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-02-22 to 2020-02-28, A's stock price decreased from 80.50 to 77.07. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 2 | A | 2020-02-22 to 2020-03-06 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-02-29 to 2020-03-06
[Next Week]: 2020-03-06 to 2020-03-13
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-03-06:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-02-29 to 2020-03-06, A's stock price decreased from 81.97 to 78.56. News during this period are listed below:
[News]:
No relevant company news reported during this week. | -12 | A | 2020-02-29 to 2020-03-13 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-03-07 to 2020-03-13
[Next Week]: 2020-03-13 to 2020-03-20
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-03-13:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-03-07 to 2020-03-13, A's stock price decreased from 70.75 to 69.20. News during this period are listed below:
[News]:
No relevant company news reported during this week. | -4 | A | 2020-03-07 to 2020-03-20 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-03-14 to 2020-03-20
[Next Week]: 2020-03-20 to 2020-03-27
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-03-20:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-03-14 to 2020-03-20, A's stock price increased from 64.13 to 66.46. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 7 | A | 2020-03-14 to 2020-03-27 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-03-21 to 2020-03-27
[Next Week]: 2020-03-27 to 2020-04-03
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-03-27:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-03-21 to 2020-03-27, A's stock price increased from 63.37 to 70.91. News during this period are listed below:
[News]:
No relevant company news reported during this week. | -1 | A | 2020-03-21 to 2020-04-03 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-03-28 to 2020-04-03
[Next Week]: 2020-04-03 to 2020-04-10
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-04-03:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-03-28 to 2020-04-03, A's stock price decreased from 72.67 to 70.42. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 11 | A | 2020-03-28 to 2020-04-10 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-04-04 to 2020-04-10
[Next Week]: 2020-04-10 to 2020-04-17
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-04-10:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-04-04 to 2020-04-10, A's stock price increased from 74.36 to 78.33. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 2 | A | 2020-04-04 to 2020-04-17 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-04-11 to 2020-04-17
[Next Week]: 2020-04-17 to 2020-04-24
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-04-17:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-04-11 to 2020-04-17, A's stock price increased from 76.21 to 79.55. News during this period are listed below:
[News]:
No relevant company news reported during this week. | -5 | A | 2020-04-11 to 2020-04-24 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-04-18 to 2020-04-24
[Next Week]: 2020-04-24 to 2020-05-01
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-04-24:
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
Quarter ending 2019-04-30 (FY 2019 Q2, currency: USD):
- Profitability: net margin 14.7%, operating margin 17.4%.
- Valuation: P/E 34.2x, P/B 4.9x, P/S 20.1x, P/FCF 116.8x.
- Balance sheet & liquidity: debt/equity 0.35, debt/assets 0.20, current ratio 3.41, quick ratio 2.82, cash ratio 1.93.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 20.4%, FCF / OCF 84.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-04-18 to 2020-04-24, A's stock price decreased from 77.37 to 75.75. News during this period are listed below:
[News]:
No relevant company news reported during this week. | -2 | A | 2020-04-18 to 2020-05-01 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-04-25 to 2020-05-01
[Next Week]: 2020-05-01 to 2020-05-08
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-05-01:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-04-25 to 2020-05-01, A's stock price decreased from 76.25 to 74.21. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 7 | A | 2020-04-25 to 2020-05-08 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-05-02 to 2020-05-08
[Next Week]: 2020-05-08 to 2020-05-15
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-05-08:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-05-02 to 2020-05-08, A's stock price increased from 74.56 to 79.71. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 2 | A | 2020-05-02 to 2020-05-15 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-05-09 to 2020-05-15
[Next Week]: 2020-05-15 to 2020-05-22
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-05-15:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
- 2019-05-14: EPS actual 0.71 / estimate 0.72 / surprise -0.01 | revenue actual 1238000000 / estimate 1488811076 / surprise -250811076
From 2020-05-09 to 2020-05-15, A's stock price increased from 81.27 to 81.59. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 4 | A | 2020-05-09 to 2020-05-22 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-05-16 to 2020-05-22
[Next Week]: 2020-05-22 to 2020-05-29
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-05-22:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-05-16 to 2020-05-22, A's stock price increased from 83.66 to 84.98. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 4 | A | 2020-05-16 to 2020-05-29 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-05-23 to 2020-05-29
[Next Week]: 2020-05-29 to 2020-06-05
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-05-29:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-05-23 to 2020-05-29, A's stock price increased from 86.13 to 88.14. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 3 | A | 2020-05-23 to 2020-06-05 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-05-30 to 2020-06-05
[Next Week]: 2020-06-05 to 2020-06-12
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-06-05:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-05-30 to 2020-06-05, A's stock price increased from 89.91 to 90.38. News during this period are listed below:
[News]:
No relevant company news reported during this week. | -5 | A | 2020-05-30 to 2020-06-12 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-06-06 to 2020-06-12
[Next Week]: 2020-06-12 to 2020-06-19
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-06-12:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-06-06 to 2020-06-12, A's stock price decreased from 90.29 to 86.11. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 3 | A | 2020-06-06 to 2020-06-19 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-06-13 to 2020-06-19
[Next Week]: 2020-06-19 to 2020-06-26
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-06-19:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-06-13 to 2020-06-19, A's stock price increased from 86.96 to 88.73. News during this period are listed below:
[News]:
No relevant company news reported during this week. | -3 | A | 2020-06-13 to 2020-06-26 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-06-20 to 2020-06-26
[Next Week]: 2020-06-26 to 2020-07-03
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-06-26:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-06-20 to 2020-06-26, A's stock price decreased from 88.53 to 85.90. News during this period are listed below:
[News]:
- (2020-06-20 06:26) Zacks: Brokerages Expect Agilent Technologies Inc (NYSE:A) Will Post Earnings of $0.63 Per Share
Summary: Brokerages predict that Agilent Technologies Inc (NYSE:A) will report $0.65 earnings per share (EPS) for the current quarter, according to Zacks. Five analysts have provided estimates for Agilent Technologies’ earnings, with estimates ranging from $0.49 to $0.73. Agilent Technologies reported earnings of $0.76 per share during the same quarter last year, which would suggest a […] | 3 | A | 2020-06-20 to 2020-07-03 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-06-27 to 2020-07-03
[Next Week]: 2020-07-03 to 2020-07-10
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-07-03:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-06-27 to 2020-07-03, A's stock price increased from 87.29 to 88.68. News during this period are listed below:
[News]:
- (2020-06-28 10:56) Agilent Technologies Inc (NYSE:A) Declares $0.18 Quarterly Dividend
Summary: Agilent Technologies Inc (NYSE:A) declared a quarterly dividend on Wednesday, May 20th, Zacks reports. Investors of record on Tuesday, June 30th will be paid a dividend of 0.18 per share by the medical research company on Wednesday, July 22nd. This represents a $0.72 dividend on an annualized basis and a yield of 0.84%. The ex-dividend […]
- (2020-06-28 12:02) Agilent Technologies Inc (NYSE:A) Shares Sold by Skandinaviska Enskilda Banken AB publ
Summary: Skandinaviska Enskilda Banken AB publ reduced its position in Agilent Technologies Inc (NYSE:A) by 1.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 74,672 shares of the medical research company’s stock after selling 1,096 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s […]
- (2020-07-01 10:32) Agilent Technologies (NYSE:A) Stock Rating Reaffirmed by Goldman Sachs Group
Summary: Agilent Technologies (NYSE:A)‘s stock had its “neutral” rating reaffirmed by equities researchers at Goldman Sachs Group in a research report issued on Wednesday, Stock Target Advisor reports. Other equities research analysts have also recently issued research reports about the company. Cfra cut their target price on Agilent Technologies from $89.00 to $85.00 and set a […]
- (2020-07-01 11:54) Agilent Technologies Inc (NYSE:A) Holdings Cut by Guggenheim Capital LLC
Summary: Guggenheim Capital LLC cut its position in Agilent Technologies Inc (NYSE:A) by 31.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,478 shares of the medical research company’s stock after selling 23,802 shares during the quarter. Guggenheim Capital LLC’s holdings in Agilent Technologies […] | 1 | A | 2020-06-27 to 2020-07-10 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-07-04 to 2020-07-10
[Next Week]: 2020-07-10 to 2020-07-17
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-07-10:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-07-04 to 2020-07-10, A's stock price increased from 89.31 to 89.42. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 6 | A | 2020-07-04 to 2020-07-17 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-07-11 to 2020-07-17
[Next Week]: 2020-07-17 to 2020-07-24
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-07-17:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-07-11 to 2020-07-17, A's stock price increased from 89.26 to 94.37. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 0 | A | 2020-07-11 to 2020-07-24 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-07-18 to 2020-07-24
[Next Week]: 2020-07-24 to 2020-07-31
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-07-24:
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
Quarter ending 2019-07-31 (FY 2019 Q3, currency: USD):
- Profitability: net margin 15.0%, operating margin 17.7%.
- Valuation: P/E 28.3x, P/B 4.6x, P/S 17.0x, P/FCF 111.6x.
- Balance sheet & liquidity: debt/equity 0.38, debt/assets 0.21, current ratio 2.13, quick ratio 1.72, cash ratio 1.09.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 19.0%, FCF / OCF 80.2%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-07-18 to 2020-07-24, A's stock price decreased from 95.21 to 94.81. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 2 | A | 2020-07-18 to 2020-07-31 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-07-25 to 2020-07-31
[Next Week]: 2020-07-31 to 2020-08-07
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-07-31:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-07-25 to 2020-07-31, A's stock price decreased from 97.27 to 96.33. News during this period are listed below:
[News]:
- (2020-07-28 12:32) Ecolab : Second Quarter Reported Diluted Continuing Operations EPS $0.44; Adjusted Diluted Continuing Operations EPS $0.65, -49% | MarketScreener
- (2020-07-28 16:44) Charting a (bullish) holding pattern, S&P 500 digests break to 5-month highs
Summary: The major U.S. benchmarks are acting well technically, though amid increasingly sideways late-July price action, writes Michael Ashbaugh.
- (2020-07-29 19:50) These ‘green’ stocks would thrive under a Biden administration, according to fund managers
Summary: ‘Energy transformation will happen with or without politicians,’ says Jonathan Waghorn of the Guinness Atkinson Alternative Energy Fund.
- (2020-07-31 16:00) Craving Healthcare: A Beginner's Guide And My 7 Picks
Summary: The Healthcare sector has significantly outperformed the S&P 500 in the last decade and with lower volatility – the only sector to do so. | 2 | A | 2020-07-25 to 2020-08-07 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-08-01 to 2020-08-07
[Next Week]: 2020-08-07 to 2020-08-14
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-08-07:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-08-01 to 2020-08-07, A's stock price decreased from 99.09 to 97.78. News during this period are listed below:
[News]:
- (2020-08-03 00:00) Samyang Biopharm USA Announces Hyun Jung Helen Lee, M.D., Named to PharmaVOICE 100
Summary: Samyang Biopharm USA, Inc. (https://us.samyangbiopharm.com) a global biotech subsidiary of the Samyang Biopharmaceuticals Corp. (https://samyangbiopha
- (2020-08-04 00:00) COVID-19 Impacts: Biotechnology Reagents Market Will Accelerate at a CAGR of about 8% through 2020-2024|Presence of High-Throughput and Novel Technologies to Boost Growth| Technavio
Summary: The Global Biotechnology Reagents Market will grow by USD 37.87 bn during 2020-2024
- (2020-08-04 06:40) Analysts Anticipate Agilent Technologies Inc (NYSE:A) Will Post Earnings of $0.54 Per Share
Summary: Analysts predict that Agilent Technologies Inc (NYSE:A) will report earnings of $0.54 per share for the current quarter, according to Zacks. Five analysts have made estimates for Agilent Technologies’ earnings, with the lowest EPS estimate coming in at $0.37 and the highest estimate coming in at $0.70. Agilent Technologies reported earnings per share of $0.76 […]
- (2020-08-04 16:38) Charting a solid August start: S&P 500, Nasdaq stage latest summer breakouts
Summary: Technically speaking, the U.S. benchmarks’ bigger-picture backdrop remains bullish amid a solid August start, writes Michael Ashbaugh.
- (2020-08-04 18:43) STERIS plc (STE) CEO Walter Rosebrough on Q1 2021 Results - Earnings Call Transcript
Summary: STERIS plc (NYSE:STE) Q1 2021 Results Conference Call August 03, 2020 10:00 AM ET Company Participants Julie Winter - Investor Relations Walter Rosebrough - President and Chief Executive Officer Michael Tokich - Senior Vice President and Chief Financial Officer Daniel Carestio - Senior Vice President and Chief Operating Officer Conference Call Participants David Turkaly - JMP Securities Christopher Cooley - Stephens Inc Michael Matson - Needham and Company Lawrence Keusch - Raymond James Matthew Mishan - KeyBanc Capital Markets Presentation Operator Good day, and welcome to the STERIS PLC First Quarter Fiscal 2021 Conference Call and Webcast.
- (2020-08-05 00:00) Analysis on Impact of COVID-19- Global Explosive Detection Equipment Market 2020-2024 | Evolving Opportunities with Agilent Technologies Inc. and Bruker Corp. | Technavio
Summary: The Global Explosive Detection Equipment Market will grow by $2.72 bn during 2020-2024
- (2020-08-06 00:00) Penn State Microbiome Center and GALT Enter Collaboration to Advance Research
Summary: Researchers will utilize GALT's Prospector high-throughput microbial isolation and cultivation system to generate banks of live microbial isolates.
- (2020-08-07 00:00) HighRadius Adds New Leader to Drive Finance Digital Transformation in Growing Enterprise Client Base
Summary: HighRadius, a fintech enterprise Software-as-a-Service (SaaS) company specializing in automating the order-to-cash and treasury management processes, | 0 | A | 2020-08-01 to 2020-08-14 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-08-08 to 2020-08-14
[Next Week]: 2020-08-14 to 2020-08-21
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-08-14:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
- 2019-08-14: EPS actual 0.76 / estimate 0.72 / surprise +0.04 | revenue actual 1274000000 / estimate 1468638888 / surprise -194638888
From 2020-08-08 to 2020-08-14, A's stock price increased from 97.14 to 97.37. News during this period are listed below:
[News]:
- (2020-08-08 00:00) Automated Test Equipment Market Highlights the Impact of COVID-19 2020-2024 | Augmented Production of Electronic Goods to Boost Market Growth | Technavio
Summary: The Global Automated Test Equipment Market will grow by USD 1.47 bn during 2020-2024
- (2020-08-08 02:16) Automated Test Equipment Market Highlights the Impact of COVID-19 2020-2024 | Augmented Production of Electronic Goods to Boost Market Growth | Technavio
- (2020-08-08 02:31) COVID-19 Impacts: PCR System for Food Diagnostics Market will Accelerate at a CAGR of over 8% through 2020-2024 | Rising Foodborne Illnesses to Boost Growth | Technavio
- (2020-08-09 18:44) Brenntag AG (BNTGF) CEO Christian Kohlpaintne on Q2 2020 Results - Earnings Call Transcript
Summary: Brenntag AG. (OTCPK:BNTGF) Q2 2020 Earnings Conference Call August 06, 2020, 08:00 AM ET Company Participants Christian Kohlpaintne - Chief Executive Officer Georg Müller - Chief Financial Officer Conference Call Participants Rory McKenzie - UBS Laurent Favre - Exane BNP Paribas Rajesh Kumar - HSBC Markus Mayer - Baader Helvea Steven Goulden - Deutsche Bank Isha Sharma - MainFirst Bank Chetan Udeshi - JPMorgan.
- (2020-08-10 00:00) Laboratory Analytical Instruments and Consumables Market Analysis Highlights the Impact of COVID-19 (2020-2024) | Rising Applications of Analytical Instruments to Boost Market Growth | Technavio
Summary: The Global Laboratory Analytical Instruments and Consumables Market will grow by USD 13.81 bn during 2020-2024
- (2020-08-11 00:00) COVID-19 Impacts: Graphite Electrode Market Will Accelerate at a CAGR of Almost 2% Through 2020-2024 | Increased Demand for High-quality Steel to Boost Growth | Technavio
Summary: The Global Graphite Electrode Market will grow by 182.85 th MT during 2020-2024
- (2020-08-11 01:40) Agilent Technologies (A) to Release Quarterly Earnings on Tuesday
Summary: Agilent Technologies (NYSE:A) will post its quarterly earnings results after the market closes on Tuesday, August 18th. Analysts expect Agilent Technologies to post earnings of $0.66 per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link. Agilent Technologies (NYSE:A) last posted its earnings […]
- (2020-08-11 16:49) Charting the approach of record highs, S&P 500 rises amid market rotation
Summary: Technically speaking, the U.S. benchmarks’ already-bullish backdrop has strengthened amid rotational August price action, writes Michael Ashbaugh. | 1 | A | 2020-08-08 to 2020-08-21 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-08-15 to 2020-08-21
[Next Week]: 2020-08-21 to 2020-08-28
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-08-21:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-08-15 to 2020-08-21, A's stock price increased from 97.51 to 98.30. News during this period are listed below:
[News]:
- (2020-08-18 00:00) A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Walmart Earnings
Summary: Pre-open movers
U.S. stock futures traded slightly higher in early pre-market trade, as investors are awaiting earnings from Walmart Inc (NYSE: WMT), Advance Auto Parts, Inc. (...
- (2020-08-18 08:00) Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent to expand state-of-the-art manufacturing capacity for nucleic acid-based therapeutics.
- (2020-08-18 16:05) Agilent Reports Third-Quarter Fiscal Year 2020 Financial Results
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent announces third quarter fiscal year 2020 financial results.
- (2020-08-18 16:41) Charting a pulling-teeth breakout attempt: S&P 500, Nasdaq challenge record territory
Summary: Technically speaking, the S&P 500 and Nasdaq Composite have registered nominal record highs this week, though a pulling-teeth breakout attempt remains...
- (2020-08-18 21:44) Agilent Technologies Inc. (A) CEO Mike McMullen on Q3 2020 Results - Earnings Call Transcript
Summary: Agilent Technologies Inc. (NYSE:A) Q3 2020 Results Conference Call August 18, 2020 04:30 PM ET Company Participants Ankur Dhingra - VP, IR Mike McMullen - President and CEO Bob McMahon - SVP and CFO Jacob Thaysen - President, Life Sciences & Applied Markets Group Sam Raha - President, Diagnostics and Genomics Group Padraig McDonnell - President, Agilent CrossLab Group Conference Call Participants Doug Schenkel - Cowen Vijay Kumar - Evercore ISI Tycho Peterson - JP Morgan Puneet Souda - Leerink Derik de Bruin - Bank of America Brandon Couillard - Jefferies Dan Leonard - Wells Fargo Catherine Schulte - Baird Steve Willoughby - Cleveland Research Dan Brennan - UBS Patrick Donnelly - Citigroup Jack Meehan - Nephron Research Presentation Operator Good afternoon, and welcome to the Agilent Technologies Third Quarter Earnings Conference Call.
- (2020-08-19 04:46) Agilent Technologies Inc. (A) Q3 2020 Earnings Call Transcript | AlphaStreet
Summary: Final earnings conference call transcript of Agilent Technologies Inc. - A stock
- (2020-08-19 06:40) Wall Street Breakfast: S&P 500 To Take Aim At New Record
Summary: Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
- (2020-08-19 12:01) Stocks making the biggest moves in the premarket: Target, Lowe's, J&J, Momenta, Gilead & more
Summary: The stocks making the biggest moves in premarket trading include Target, Lowe's, J&J, Momenta, Gilead, and more.
- (2020-08-19 18:15) Agilent Technologies, Inc. 2020 Q3 - Results - Earnings Call Presentation
Summary: The following slide deck was published by Agilent Technologies, Inc. in conjunction with their 2020 Q3 earnings call.. | 2 | A | 2020-08-15 to 2020-08-28 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-08-22 to 2020-08-28
[Next Week]: 2020-08-28 to 2020-09-04
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-08-28:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-08-22 to 2020-08-28, A's stock price increased from 97.60 to 99.90. News during this period are listed below:
[News]:
- (2020-08-22 00:00) COVID-19 Impacts: Global Metabolomics Market will Accelerate at a CAGR of over 12% through 2020-2024 | Increased Adoption in the Field of Precision Medicine to Boost Growth | Technavio
Summary: The Global Metabolomics Market will grow by $ 1.54 bn during 2020-2024
- (2020-08-25 00:00) Global Anatomic Pathology Market Analysis 2020-2025 - by Product & Service, Consumables, Application, End User and Region - ResearchAndMarkets.com
Summary: The
- (2020-08-25 03:34) $0.91 Earnings Per Share Expected for Agilent Technologies Inc (NYSE:A) This Quarter
Summary: Wall Street analysts expect Agilent Technologies Inc (NYSE:A) to report earnings per share (EPS) of $0.91 for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Agilent Technologies’ earnings. The lowest EPS estimate is $0.85 and the highest is $1.00. Agilent Technologies reported earnings of $0.89 per share during the same […]
- (2020-08-26 00:00) Global Genetic Testing Market Size Forecast to 2023 - ResearchAndMarkets.com
Summary: The
- (2020-08-27 00:00) Agilent Sets the Standard in Customer Flexibility with Analytical Technology Subscription Model
Summary: Agilent Technologies Inc. (NYSE: A) today announced its first-ever instrument subscription program, designed to meet the needs of customers with dynam
- (2020-08-27 06:46) Virtu Financial LLC Buys Shares of 2,379 Agilent Technologies Inc (NYSE:A)
Summary: Virtu Financial LLC acquired a new stake in Agilent Technologies Inc (NYSE:A) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,379 shares of the medical research company’s stock, valued at approximately $210,000. Other institutional investors also recently bought and sold […]
- (2020-08-27 08:00) Agilent Sets the Standard in Customer Flexibility with Analytical Technology Subscription Model
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. | -3 | A | 2020-08-22 to 2020-09-04 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-08-29 to 2020-09-04
[Next Week]: 2020-09-04 to 2020-09-11
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-09-04:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-08-29 to 2020-09-04, A's stock price decreased from 100.42 to 96.84. News during this period are listed below:
[News]:
- (2020-08-31 13:45) Pershing Square Holdings Semi-Annual Letter To Shareholders
Summary: Pershing Square Holdings, Ltd. is a closed-ended investment company.
- (2020-09-01 08:00) Agilent Announces SureSelect XT HS2 RNA Reagent Kit, a Library Prep and Target Enrichment Solution for RNA-Seq
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc.
- (2020-09-02 10:23) Tracking Bill Ackman's Pershing Square Portfolio - Q2 2020 Update
Summary: Bill Ackman’s 13F portfolio value increased from $6.57B to $7.75B this quarter. Pershing Square increased Restaurant Brands while dropping Berkshire Hathaway during the quarter. | 2 | A | 2020-08-29 to 2020-09-11 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-09-05 to 2020-09-11
[Next Week]: 2020-09-11 to 2020-09-18
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-09-11:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-09-05 to 2020-09-11, A's stock price increased from 95.14 to 98.60. News during this period are listed below:
[News]:
- (2020-09-05 08:21) Stocks To Watch: Tech Reboots And Eyes On Lululemon, Peloton & GameStop
Summary: Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- (2020-09-06 04:42) Wall Street Breakfast: The Week Ahead
Summary: Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
- (2020-09-11 10:49) Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2020 Update
Summary: Halvorsen's 13F portfolio value increased from $19.21B to $23.14B. The number of positions increased from 64 to 71. | 1 | A | 2020-09-05 to 2020-09-18 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-09-12 to 2020-09-18
[Next Week]: 2020-09-18 to 2020-09-25
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-09-18:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-09-12 to 2020-09-18, A's stock price remained roughly flat from 99.42 to 99.38. News during this period are listed below:
[News]:
- (2020-09-15 00:00) Spectrophotometer Market: COVID-19 Business Continuity Plan | Evolving Opportunities With Agilent Technologies Inc. and Avantor Inc. | Technavio
Summary: The Global Spectrophotometer Market will grow by $ 869.24 mn during 2020-2024
- (2020-09-16 00:00) In Vitro Diagnostic (IVD) Reagents (Antibodies, Oligonucleotide, Nucleic Acid Probe) Market - Global Forecast to 2027 - ResearchAndMarkets.com
Summary: The
- (2020-09-16 16:05) Agilent Announces Cash Dividend of 18 Cents Per Share
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent announces dividend of 18 cents per share.
- (2020-09-17 00:00) Chromatography Market- Roadmap for Recovery from COVID-19 | Growing Demand For Portable Analytical Systems to boost the Market Growth | Technavio
Summary: The Global Chromatography Market will grow by $ 4.13 bn during 2020-2024
- (2020-09-17 06:30) Agilent Technologies Inc (NYSE:A) Shares Sold by Fmr LLC
Summary: Fmr LLC decreased its stake in shares of Agilent Technologies Inc (NYSE:A) by 5.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 353,733 shares of the medical research company’s stock after selling 18,800 shares during the quarter. Fmr LLC owned about 0.11% […]
- (2020-09-17 08:00) Agilent Expands Line of Innovative Flow Cytometers with the NovoCyte Penteon
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc.
- (2020-09-17 14:17) Tracking William Nygren's Harris Associates Portfolio - Q2 2020 Update (MUTF:OAKMX)
Summary: Harris Associates 13F portfolio value increased from $36.11B to $41.11B this quarter. They increased Workday while reducing Regeneron Pharmaceuticals. | -2 | A | 2020-09-12 to 2020-09-25 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-09-19 to 2020-09-25
[Next Week]: 2020-09-25 to 2020-10-02
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-09-25:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-09-19 to 2020-09-25, A's stock price decreased from 98.13 to 97.69. News during this period are listed below:
[News]:
- (2020-09-21 00:00) Laboratory Equipment Services Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024
Summary: The Laboratory Equipment Services market will register an incremental spend of about $24 billion, growing at a CAGR of 6.23%.
- (2020-09-21 08:22) AdvisorNet Financial Inc Has $113,000 Position in Agilent Technologies Inc (NYSE:A)
Summary: AdvisorNet Financial Inc reduced its position in shares of Agilent Technologies Inc (NYSE:A) by 10.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,282 shares of the medical research company’s stock after selling 148 shares during the period. AdvisorNet Financial Inc’s […]
- (2020-09-22 00:00) Instrumentation Services Market: COVID-19 Business Continuity Plan | Evolving Opportunities With ABB Ltd. and Agilent Technologies Inc. | Technavio
Summary: The Global Instrumentation Services Market will grow by $ 1.31 bn during 2020-2024
- (2020-09-22 16:05) Quantum Genomics :
Quantum Genomics conclut un accord de licence et de collaboration exclusif avec Orient EuroPharma (OEP) | Zone bourse
- (2020-09-23 00:00) COVID-19 Recovery Analysis: Explosive Detection Equipment Market | Enhanced Security Mandate of Authorities to Boost the Market Growth | Technavio
Summary: The Global Explosive Detection Equipment Market will grow by $ 2.72 bn during 2020-2024
- (2020-09-25 00:00) Insights on the Predictive and Presymptomatic Testing Global Market to 2027 - Featuring Mapmygenome, Myriad Genetics & Pathway Genomics Among Others - ResearchAndMarkets.com
Summary: The | 2 | A | 2020-09-19 to 2020-10-02 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-09-26 to 2020-10-02
[Next Week]: 2020-10-02 to 2020-10-09
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-10-02:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-09-26 to 2020-10-02, A's stock price increased from 99.51 to 100.01. News during this period are listed below:
[News]:
- (2020-09-29 00:00) COVID-19 Recovery Analysis: Protein Expression Market | Increasing Advances in Proteomics Research to Boost Market Growth | Technavio
Summary: The Global Protein Expression Market will grow by $ 1.63 bn during 2020-2024
- (2020-09-30 00:00) Global Laboratory Centrifuge Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024
Summary: The Global Laboratory Centrifuge market will register an incremental spend of about $292 million, growing at a CAGR of 3.42%
- (2020-10-02 00:00) Global Single Cell Genomics Markets, 2020-2024 with COVID-19 Updates (Q3 2020) - ResearchAndMarkets.com
Summary: The | 6 | A | 2020-09-26 to 2020-10-09 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-10-03 to 2020-10-09
[Next Week]: 2020-10-09 to 2020-10-16
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-10-09:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-10-03 to 2020-10-09, A's stock price increased from 103.12 to 105.76. News during this period are listed below:
[News]:
- (2020-10-06 00:00) Cell Isolation Market to reach USD 9.47 bn by 2024, Agilent Technologies Inc. and Becton, Dickinson and Co. emerge as Key Contributors to Growth| Technavio
Summary: The Global Cell Isolation Market will grow by USD 9.47 bn during 2020-2024
- (2020-10-06 00:00) Wellcome Sanger Institute selecciona a Arima Genomics como su socio tecnológico de HiC; la compañía anuncia un programa de acceso temprano para la tecnología HiC de alta cobertura
Summary: Arima Genomics, Inc., una compañía de biotecnología que tiene como objetivo acelerar la adopción de la información de la estructura del genoma, anunci
- (2020-10-06 11:15) Disruptive Technologies Are Enabling The Re-Opening Economy
Summary: Sandwiched between the two extremes of the largely shut-down Stay-at-Home Economy and a fully opened New Normal Economy, the Re-Opening Economy is an uncertain, transitional phase.
- (2020-10-07 00:00) COVID-19 Impact and Recovery Analysis | Laboratory Equipment Services Market Procurement Intelligence Report Forecasts Spend Growth of Over USD 24 Billion | SpendEdge
Summary: Global Laboratory Equipment Services Market is poised to experience spend growth of more than USD 24 billion between 2020-2024 at a CAGR of over 6.23%
- (2020-10-07 09:38) Global Womens Health Diagnostics Market Investment Feasibility 2029 With Top Manufactures - Agilent Technologies, Ariosa Diagnostics
Summary: Oct 07, 2020 (WiredRelease via Comtex) --
Radical Growth of Global Womens Health Diagnostics Market Provides an updated and current analysis of the...
- (2020-10-08 00:00) Global Biosensors in Life Sciences Market Will Showcase Neutral Impact During 2020-2024 | Advantages of Biosensors in Drug Analysis to Boost Market Growth | Technavio
Summary: The Global Biosensors in Life Sciences Market will grow by $ 2.32 bn during 2020-2024
- (2020-10-08 07:56) Fulton Bank N. A. Has $654,000 Stock Position in Agilent Technologies Inc (NYSE:A)
Summary: Fulton Bank N. A. grew its holdings in shares of Agilent Technologies Inc (NYSE:A) by 17.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,480 shares of the medical research company’s stock after buying an additional 957 shares during the quarter. […]
- (2020-10-08 07:56) Agilent Technologies Inc (NYSE:A) Shares Sold by First Hawaiian Bank
Summary: First Hawaiian Bank trimmed its holdings in shares of Agilent Technologies Inc (NYSE:A) by 2.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,496 shares of the medical research company’s stock after selling 336 shares during the quarter. First Hawaiian Bank’s holdings in […]
- (2020-10-08 10:32) Agilent Announces the Availability of Objective Decision Support for Pathologists Reviewing Breast Cancer Cases
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the expansion of Visiopharm’s validated image analysis algorithm to incorporate HercepTest™ mAb pharmDx for Dako Omnis, both CE-IVD marked and recently released for sale in Europe. This development enables pathologists to use the Visiopharm HER2 APP for objective decision support in the assessment of HercepTest™ mAb pharmDx stained slides, saving valuable time for both pathologists and patients. The Hercep
- (2020-10-09 00:00) Genomics Market| Need for Creating/Upgrading Genome Databases to Boost the Market Growth | Technavio
Summary: The Global Genomics Market will grow by USD 17.23 bn during 2020-2024 | 1 | A | 2020-10-03 to 2020-10-16 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-10-10 to 2020-10-16
[Next Week]: 2020-10-16 to 2020-10-23
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-10-16:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-10-10 to 2020-10-16, A's stock price increased from 105.43 to 106.70. News during this period are listed below:
[News]:
- (2020-10-12 00:00) Top Sector ETFs From Wall Street's Best Week in 3 Months
Summary: Stocks Analysis by Zacks Investment Research covering: S&P 500, Xilinx Inc, NVIDIA Corporation, Advanced Micro Devices Inc. Read Zacks Investment Research's latest article on Investing.com
- (2020-10-13 00:00) DNA Sequencing Market to Reach $ 12.5 bn by 2024, Agilent Technologies Inc., BGI Genomics Co. Ltd., and Thermo Fisher Scientific Inc., Emerge as Key Contributors to Growth | Technavio
Summary: The Global DNA Sequencing Market will grow by USD 12.5 bn during 2020-2024
- (2020-10-13 09:14) Agilent Technologies Inc (NYSE:A) Stock Position Increased by LGT Capital Partners LTD.
Summary: LGT Capital Partners LTD. increased its stake in shares of Agilent Technologies Inc (NYSE:A) by 3.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 829,680 shares of the medical research company’s stock after purchasing an additional 26,210 shares during the period. Agilent Technologies makes […]
- (2020-10-14 08:00) Agilent Early Career Professor Award Presented to Carl DeSelm
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Carl DeSelm, M.D., Ph.D., has received the 2020 Agilent Early Career Professor Award. Dr. DeSelm is an assistant professor of Radiation Oncology at the Washington University School of Medicine in St. Louis, MO. This years’ award topic is cellular engineering and analysis—a field that greatly impacts Agilent customers. The DeSelm lab’s current research focuses on the engineering and clinical developmen
- (2020-10-14 08:14) Agilent Technologies Inc (NYSE:A) Shares Acquired by Envestnet Asset Management Inc.
Summary: Envestnet Asset Management Inc. grew its stake in Agilent Technologies Inc (NYSE:A) by 10.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 256,741 shares of the medical research company’s stock after purchasing an additional 24,832 shares during the period. Envestnet Asset […]
- (2020-10-15 00:00) Global Treatment and Diagnosis of Sexually Transmitted Diseases Markets, 2025 - Focus on Antibiotics, Antivirals/Antiretrovirals & EIA, ELISA, PCR, Rapid Diagnostics - ResearchAndMarkets.com
Summary: The
- (2020-10-15 08:00) Agilent Vaya Raman Raw Material ID Verification System Receives 2020 R&D 100 Award
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the Agilent Vaya Raman raw material identity verification system has received a 2020 R&D 100 Award in the Analytical/Test category. The worldwide competition, held by R&D World, recognizes R&D pioneers and their revolutionary contributions to science and technology. Agilent’s award-winning product is the first handheld Raman spectrometer incorporating spatially offset Raman spectroscopy (S
- (2020-10-16 00:00) Global Capillary Electrophoresis Market|Increasing R&D Expenditure to Boost Market Growth | Technavio
Summary: The Global Capillary Electrophoresis Market will grow by $ 300.97 mn during 2020-2024
- (2020-10-16 07:22) Regentatlantic Capital LLC Sells 474 Shares of Agilent Technologies Inc (NYSE:A)
Summary: Regentatlantic Capital LLC cut its holdings in Agilent Technologies Inc (NYSE:A) by 7.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,768 shares of the medical research company’s stock after selling 474 shares during the quarter. Regentatlantic Capital LLC’s holdings in […]
- (2020-10-16 08:16) CX Institutional Purchases 299 Shares of Agilent Technologies Inc (NYSE:A)
Summary: CX Institutional lifted its position in shares of Agilent Technologies Inc (NYSE:A) by 130.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 528 shares of the medical research company’s stock after acquiring an additional 299 shares during the period. CX […] | 0 | A | 2020-10-10 to 2020-10-23 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-10-17 to 2020-10-23
[Next Week]: 2020-10-23 to 2020-10-30
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-10-23:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-10-17 to 2020-10-23, A's stock price increased from 105.49 to 106.17. News during this period are listed below:
[News]:
- (2020-10-18 00:00) COVID-19 Impact and Recovery Analysis |Laboratory Equipment Services Market Procurement Intelligence Report Forecasts Spend Growth of over USD 24 Billion
Summary: Laboratory Equipment Services Market is poised to experience spend growth of more than USD 24 billion between 2020-2024 at a CAGR of over 6.23%.
- (2020-10-18 04:58) Nachman Norwood & Parrott Inc Makes New Investment in Agilent Technologies Inc (NYSE:A)
Summary: Nachman Norwood & Parrott Inc purchased a new position in Agilent Technologies Inc (NYSE:A) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 515 shares of the medical research company’s stock, valued at approximately $52,000. A number of other institutional investors and hedge funds […]
- (2020-10-19 00:00) Agilent to Showcase Their Commitment to Sustainability at analytica virtual 2020
Summary: Agilent Technologies Inc. (NYSE: A) today announced that their 1220, 1260, and 1290 Infinity II LC product families have received the My Green Lab acc
- (2020-10-19 06:00) QUANTUM GENOMICS : Quantum Genomics conclut un accord de licence et de collaboration exclusif avec Qilu Pharmaceutical
Summary: Quantum Genomics recevra jusqu'à 50 M$ de paiements initiaux (upfront) et d'étapes (milestones) ainsi que des royalties à deux chiffres sur les ventes futures.
Qilu Pharmaceutical recevra une licence exclusive pour développer et commercialiser le firibastat pour le traitement de l'hypertension difficile à traiter / résistante en Chine, y compris Hong-Kong et Macao
- (2020-10-19 06:05) Quantum Genomics :
Quantum Genomics conclut un accord de licence et de collaboration exclusif avec Qilu Pharmaceutical | Zone bourse
- (2020-10-19 06:18) Mission Wealth Management LP Buys 101 Shares of Agilent Technologies, Inc. (NYSE:A)
Summary: Mission Wealth Management LP increased its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 1.1% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,539 shares of the medical research company’s stock after acquiring an additional 101 shares during the quarter. Mission […]
- (2020-10-19 07:38) Agilent to Showcase Their Commitment to Sustainability at analytica virtual 2020
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that their 1220, 1260, and 1290 Infinity II LC product families have received the My Green Lab accountability, consistency, and transparency (ACT) certification. Recognition of these products by My Green Lab highlights Agilent's commitment to pursuing sustainability throughout the production and lifecycle of its analytical equipment. Agilent will showcase these accredited products at the 2020 analytica vir
- (2020-10-20 00:00) Validation of Bluestar Genomics’ Technology for Non-Invasive Detection of Pancreatic Cancer Published in Nature Communications
Summary: Bluestar Genomics, an innovative company leading the development of next-generation epigenomic approaches to early cancer detection, announced today t
- (2020-10-20 06:40) Agilent Technologies, Inc. (NYSE:A) Shares Purchased by IBM Retirement Fund
Summary: IBM Retirement Fund boosted its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 39.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,053 shares of the medical research company’s stock after buying an additional 2,821 shares during […]
- (2020-10-22 07:41) Pacer Advisors Inc. Sells 4,329 Shares of Agilent Technologies, Inc. (NYSE:A)
Summary: Pacer Advisors Inc. lowered its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 13.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,835 shares of the medical research company’s stock after selling 4,329 shares during the quarter. Pacer Advisors Inc.’s holdings in Agilent […] | -4 | A | 2020-10-17 to 2020-10-30 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-10-24 to 2020-10-30
[Next Week]: 2020-10-30 to 2020-11-06
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-10-30:
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
Quarter ending 2019-10-31 (FY 2019 Q4, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.3%.
- Valuation: P/E 30.2x, P/B 4.9x, P/S 17.1x, P/FCF 82.4x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 1.53, quick ratio 1.21, cash ratio 0.66.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales 23.0%, FCF / OCF 90.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-10-24 to 2020-10-30, A's stock price decreased from 104.63 to 102.09. News during this period are listed below:
[News]:
- (2020-10-26 17:15) Bill Ackman Reduces Lowe's, Agilent Technologies and Hilton Worldwide Holdings
Summary: Bill Ackman (Trades, Portfolio), leader of Pershing Square Capital Management, has revealed his portfolio for the third quarter.
- (2020-10-29 15:00) Agilent to Webcast Fourth-Quarter Fiscal Year 2020 Financial Results Presentation, Sets Date for Virtual Analyst and Investor Meeting
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent will release fiscal fourth quarter financial results Mon., Nov. 23. and will also host a virtual analyst and investor event Wed., Dec. 9.
- (2020-10-29 15:00) Agilent to Webcast Fourth-Quarter Fiscal Year 2020 Financial Results Presentation, Sets Date for Virtual Analyst and Investor Meeting
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release fourth-quarter fiscal year 2020 financial results after the stock market closes on Monday, Nov. 23. The company will host a live webcast of its investor conference call in listen-only mode on the same day. The company will also host an Analyst and Investor meeting on Wednesday, Dec. 9. The meeting, which will be conducted in a virtual format, will include presentations by Agilent’s senior management team on the company’s long-range strategies for accelerating revenue growth and shareholder value creation. The meeting will include a live question and answer session following the presentations. Details for both webcasts: Agilent Fourth-Quarter Earnings Webcast Monday, Nov. 23, 2020 at 1:30 p.m. Pacific time Agilent 2020 Virtual Analyst and Investor Meeting Wednesday, Dec. 9, 2020 at 7 a.m. Pacific time Links to the events will be provided in the “News & Events -- Events” portion of the Investor Relations section of the Agilent website. The webcasts will remain on the company site for 90 days. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook. | 10 | A | 2020-10-24 to 2020-11-06 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-10-31 to 2020-11-06
[Next Week]: 2020-11-06 to 2020-11-13
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-11-06:
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-10-31 to 2020-11-06, A's stock price increased from 105.24 to 112.54. News during this period are listed below:
[News]:
- (2020-11-04 08:00) Agilent Collaborates With SGS to Release New US EPA Method for the Analysis of Dioxins Using GC/TQ
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today a collaboration with SGS has resulted in a new GC/TQ method, the SGS AXYS Method 16130, approved by the US EPA as an alternative method for the future regulation and detection of dioxins. Dioxins are a group of chemical compounds that are considered persistent environmental pollutants and subsequently find their way into the food chain. These chemicals are listed as persistent organic pollutants under the | -2 | A | 2020-10-31 to 2020-11-13 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-11-07 to 2020-11-13
[Next Week]: 2020-11-13 to 2020-11-20
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-11-13:
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-11-07 to 2020-11-13, A's stock price decreased from 112.50 to 110.17. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 1 | A | 2020-11-07 to 2020-11-20 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-11-14 to 2020-11-20
[Next Week]: 2020-11-20 to 2020-11-27
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-11-20:
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
- 2019-11-25: EPS actual 0.89 / estimate 0.86 / surprise +0.03 | revenue actual 1367000000 / estimate 1732593023 / surprise -365593023
From 2020-11-14 to 2020-11-20, A's stock price increased from 110.27 to 110.89. News during this period are listed below:
[News]:
- (2020-11-17 08:32) Agilent Presents Thought Leader Award to Drs. Carl H. June and Michael Milone
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced professors Carl H. June, MD, and Michael Milone, MD, Ph.D., as recipients of an Agilent Thought Leader Award. Both scientists are being recognized for their joint contributions to the field of CAR T-cell mediated cancer immunotherapy, having codeveloped tisagenlecleucel (Kymriah™), the first cell and gene therapy product approved by the US FDA. The award will focus on defining standards for the design, val
- (2020-11-18 16:05) Agilent Increases Cash Dividend to 19.4 Cents Per Share
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent increases the company's quarterly dividend to 19.4 cents per share of common stock, reflecting an 8% increase over the previous quarter. | 3 | A | 2020-11-14 to 2020-11-27 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-11-21 to 2020-11-27
[Next Week]: 2020-11-27 to 2020-12-04
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-11-27:
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
From 2020-11-21 to 2020-11-27, A's stock price increased from 112.21 to 114.09. News during this period are listed below:
[News]:
- (2020-11-23 08:00) Agilent Launches New NanoDis System for Nanoparticle Dissolution Testing
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of the NanoDis System for nanoparticle dissolution testing. Combining Agilent instrumentation and software to enable customers to meet 21 CFR Part 11 and other regulations through its application, the new NanoDis System delivers a dedicated workflow that is automatable and auditable. Designed in collaboration with Dr. Emre Türeli from nanoparticle manufacturer MyBiotech GmbH, the NanoDis S
- (2020-11-23 09:00) Dividend Changes: November 14-20, 2020
Summary: In this article series, we provide a weekly summary of dividend changes. A summary table provides relevant data and key statistics of dividend increases.
- (2020-11-23 16:05) Agilent Reports Fourth-Quarter and Fiscal Year 2020 Financial Results; Initiates Fiscal 2021 Guidance
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent reports fourth-quarter and fiscal year 2020 financial results; initiates fiscal 2021 guidance.
- (2020-11-23 16:29) Agilent Technologies: Q4 Earnings Insights
Summary: Shares of Agilent Technologies (NYSE:A) fell 2.53% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 10.11% over the past year to $0.98, which beat the estimate of $0.93.
- (2020-11-23 20:15) Agilent Technologies Inc. (A) CEO Mike McMullen on Q4 2020 Results - Earnings Call Transcript
Summary: Agilent Technologies Inc. (A) CEO Mike McMullen on Q4 2020 Results - Earnings Call Transcript | 1 | A | 2020-11-21 to 2020-12-04 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-11-28 to 2020-12-04
[Next Week]: 2020-12-04 to 2020-12-11
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-12-04:
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
From 2020-11-28 to 2020-12-04, A's stock price decreased from 116.90 to 115.15. News during this period are listed below:
[News]:
- (2020-11-30 08:00) Agilent Announces Launch of Global Biomarker Pathologist Training Program
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Biomarker Pathologist Training Program, a global initiative created to empower pathologists to score biomarkers accurately and confidently. Developed by Agilent – a worldwide leader in developing and commercializing diagnostic products – this training program incorporates Agilent's unique expertise in companion diagnostics and partnership with top pharmaceutical companies. Biomarker testi
- (2020-12-02 08:00) Agilent Announces New, Innovative 7850 ICP-MS System
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a new ICP-MS instrument, the Agilent 7850 ICP-MS System, that provides new smart tools to minimize common time traps that can affect ICP-MS analysis workflows. Building on decades of innovation, the 7850 ICP-MS combines market-leading performance with new smart software features that bring advanced capabilities to the routine ICP-MS laboratory. The new 7850 provides solutions that enable customers to be mo | 3 | A | 2020-11-28 to 2020-12-11 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-12-05 to 2020-12-11
[Next Week]: 2020-12-11 to 2020-12-18
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-12-11:
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
From 2020-12-05 to 2020-12-11, A's stock price increased from 114.40 to 118.48. News during this period are listed below:
[News]:
- (2020-12-07 00:30) Agilent Presents Thought Leader Award to IIT Delhi Scientist Professor Anurag Rathore
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) has honored Prof. Anurag Rathore, a scientist at the Indian Institute of Technology (IIT) Delhi, with an Agilent Thought Leader Award, for his contributions to the field of biopharmaceutical research and his work with advanced methods for molecular characterization of biosimilars. The 2020 award includes a grant to support research personnel and Agilent instrumentation including a 6545XT AdvanceBio LC/Q-TOF, a Bravo Autom | 1 | A | 2020-12-05 to 2020-12-18 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-12-12 to 2020-12-18
[Next Week]: 2020-12-18 to 2020-12-25
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-12-18:
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
From 2020-12-12 to 2020-12-18, A's stock price increased from 116.74 to 119.30. News during this period are listed below:
[News]:
- (2020-12-14 08:00) Agilent Receives Multiple Innovation Awards
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that both the NanoDis System and the innovative new style polychromator in the 5800 and 5900 ICP-OES have received Innovation Awards from The Analytical Scientist. The recently launched NanoDis System utilizes cross-flow filtration—a concept traditionally used in industrial process chemistry—combined with conventional dissolution instruments to enable nanoparticle dissolution testing. Along with the introd
- (2020-12-16 11:00) Agilent Announces Webcasts for Investment Community
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent announces investor webcasts. | -2 | A | 2020-12-12 to 2020-12-25 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-12-19 to 2020-12-25
[Next Week]: 2020-12-25 to 2021-01-01
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2020-12-25:
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
From 2020-12-19 to 2020-12-25, A's stock price decreased from 117.78 to 117.31. News during this period are listed below:
[News]:
- (2020-12-22 22:00) Agilent Receives Approval for GenetiSure Dx Postnatal Assay in Japan
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced it has obtained clearance from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the GenetiSure Dx Postnatal Assay – a microarray-based assay for diagnostic use. This assay enables clinical geneticists to detect genetic aberrations associated with developmental delay, intellectual disabilities, congenital anomalies, and unexplained dysmorphic features. The company also announced that it has register
- (2020-12-23 12:03) Why Is Agilent (A) Up 2.4% Since Last Earnings Report?
Summary: Agilent (A) reported earnings 30 days ago. What's next for the stock? | 1 | A | 2020-12-19 to 2021-01-01 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2020-12-26 to 2021-01-01
[Next Week]: 2021-01-01 to 2021-01-08
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-01-01:
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
From 2020-12-26 to 2021-01-01, A's stock price increased from 117.83 to 118.49. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 7 | A | 2020-12-26 to 2021-01-08 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-01-02 to 2021-01-08
[Next Week]: 2021-01-08 to 2021-01-15
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-01-08:
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
From 2021-01-02 to 2021-01-08, A's stock price increased from 118.64 to 127.06. News during this period are listed below:
[News]:
No relevant company news reported during this week. | -1 | A | 2021-01-02 to 2021-01-15 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-01-09 to 2021-01-15
[Next Week]: 2021-01-15 to 2021-01-22
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-01-15:
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
From 2021-01-09 to 2021-01-15, A's stock price decreased from 128.15 to 126.21. News during this period are listed below:
[News]:
- (2021-01-15 10:48) 5 Health Care Stocks Gurus Are Buying
Summary: According to the GuruFocus All-in-One Screener as of Jan. 15, the following Health Care stocks are popular among gurus.
- (2021-01-15 13:37) Agilent Names Allison Ballmer Senior Vice President of Strategy and Corporate Development
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent names Allison Ballmer senior vice president of Strategy and Corporate Development. | 0 | A | 2021-01-09 to 2021-01-22 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-01-16 to 2021-01-22
[Next Week]: 2021-01-22 to 2021-01-29
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-01-22:
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
From 2021-01-16 to 2021-01-22, A's stock price decreased from 127.35 to 126.33. News during this period are listed below:
[News]:
No relevant company news reported during this week. | -5 | A | 2021-01-16 to 2021-01-29 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-01-23 to 2021-01-29
[Next Week]: 2021-01-29 to 2021-02-05
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-01-29:
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
Quarter ending 2020-01-31 (FY 2020 Q1, currency: USD):
- Profitability: net margin 14.5%, operating margin 15.8%.
- Valuation: P/E 32.5x, P/B 5.3x, P/S 18.9x, P/FCF -275.2x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.26, current ratio 1.64, quick ratio 1.27, cash ratio 0.65.
- Efficiency & cash flow: asset turnover 0.14x, OCF / sales -4.3%, FCF / OCF 157.6%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
From 2021-01-23 to 2021-01-29, A's stock price decreased from 125.48 to 120.17. News during this period are listed below:
[News]:
- (2021-01-25 08:00) Agilent Announces Enhanced Mass Spectrometry and Automation Software Solutions to Support Regulatory Compliance Guidelines
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of MassHunter Workstation Plus 11.0, MassHunter Networked Workstation 11.0, and MassHunter BioConfirm. The latest revision of these software enables data integrity consistent with the regulatory requirements from the US FDA and EU EMEA guidance, providing user management, checksums, tamper detection, and audit trails for MassHunter Acquisition, Quantitative Analysis, and MassHunter BioConfirm.
- (2021-01-26 11:00) Agilent to Webcast First-Quarter Fiscal Year 2021 Financial Results Presentation
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent to issue first quarter fiscal year 2021 financial results Tuesday, Feb. 16.
- (2021-01-27 22:31) Agilent Technologies: Latest Guidance Increase Points Toward A Brighter Outlook
Summary: Agilent raises its FQ1 '21 guide at the recent JPM conference on the back of broad-based strength across its segments and end-markets. The near-term outlook appears bright, underpinned by a cyclical rebound in the Life Science & Applied Markets business, along with continued resilience in the Cross Lab Group. | 3 | A | 2021-01-23 to 2021-02-05 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-01-30 to 2021-02-05
[Next Week]: 2021-02-05 to 2021-02-12
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-02-05:
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
From 2021-01-30 to 2021-02-05, A's stock price increased from 120.83 to 123.18. News during this period are listed below:
[News]:
- (2021-02-01 11:00) Agilent Wins Trade Secret and Patent Infringement Litigation
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent wins trade secret and patent Infringement ruling; J&X Technologies to pay Agilent more than $1.25 million in damages. | 4 | A | 2021-01-30 to 2021-02-12 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-02-06 to 2021-02-12
[Next Week]: 2021-02-12 to 2021-02-19
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-02-12:
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
- 2020-02-18: EPS actual 0.81 / estimate 0.81 / surprise +0.00 | revenue actual 1357000000 / estimate 1641802469 / surprise -284802469
From 2021-02-06 to 2021-02-12, A's stock price increased from 123.41 to 127.98. News during this period are listed below:
[News]:
- (2021-02-08 14:00) Agilent to Present at Upcoming Investor Events; Provides Webcast Details for Annual Shareholder Meeting
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent announces upcoming investor events and details for annual Shareholder Meeting.
- (2021-02-09 12:53) What Makes Agilent (A) a New Buy Stock
Summary: Agilent (A) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- (2021-02-09 13:38) Agilent Technologies (A) Earnings Expected to Grow: Should You Buy?
Summary: Agilent (A) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- (2021-02-12 08:20) What's in the Offing for Agilent (A) This Earnings Season?
Summary: Agilent's (A) strength in revenue segments is likely to reflect on fiscal first-quarter results. | -1 | A | 2021-02-06 to 2021-02-19 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-02-13 to 2021-02-19
[Next Week]: 2021-02-19 to 2021-02-26
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-02-19:
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
From 2021-02-13 to 2021-02-19, A's stock price decreased from 127.95 to 126.87. News during this period are listed below:
[News]:
- (2021-02-16 16:05) Agilent Reports First-Quarter Fiscal Year 2021 Financial Results
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #AgilentQ1--Agilent announces strong first quarter financial results; raises outlook for full year.
- (2021-02-16 16:10) Agilent Technologies shares up 2% on better-than-expected earnings, sales
Summary: Shares of Agilent Technologies Inc. were up 2% in after-hours trading Tuesday after the life-sciences and diagnostics company reported fiscal first-quarter results. Agilent reported net income of $288 million, or 93 cents a share, compared with net income of $197 million, or 63 cents a share, in the year-ago quarter.
- (2021-02-16 16:20) Recap: Agilent Technologies Q1 Earnings
Summary: Shares of Agilent Technologies (NYSE:A) moved higher after the company reported Q1 results. Quarterly Results Earnings per share rose 30.86% over the past year to $1.06, which beat the estimate of $0.89.
- (2021-02-16 21:29) Agilent Technologies Inc. (A) CEO Mike McMullen on Q1 2021 Results - Earnings Call Transcript
Summary: Agilent Technologies Inc. (A) CEO Mike McMullen on Q1 2021 Results - Earnings Call Transcript
- (2021-02-17 08:00) Agilent Announces Higher-Sensitivity XF Analysis Solution for Low Abundant Immune Cell Metabolic Analysis
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today introduced the Agilent Seahorse XF HS Miniplate designed specifically for the Agilent Seahorse XF HS Mini Analyzer for improved immune cell metabolic analysis. Immunology and disease researchers are increasingly using rare, ex vivo, and genetically engineered cells to build better disease models. Limitations in the quantities of these cells that they can produce, however, restrict these researchers in the types of c
- (2021-02-17 10:36) Agilent's (A) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Summary: Agilent Technologies' (A) fiscal first-quarter results reflect growth in all segments and regions served.
- (2021-02-18 08:00) Agilent Announces Immunoassay Kit to Detect SARS-CoV-2 Antibodies
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit intended for the qualitative detection of immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum or plasma. The kit, which marks Agilent's entrance into SARS-CoV-2 testing in the US, has completed the notification process to FDA in accordance with Section IV.D of FDA's “Policy for Coronavirus Disease-2019 Te
- (2021-02-18 17:36) Agilent Ranks No. 2 on Barron's List of America's Most Sustainable Companies
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) has earned the number two position on Barron's annual list of America's Most Sustainable Companies. The ranking marks the third straight year Agilent has been included among the top three Most Sustainable Companies. Agilent has also received the number one ranking in the life sciences industry for each of the four years the Barron's ranking has been compiled. “We're very pleased to again be named one of America's Most Sus
- (2021-02-19 14:15) Bill Ackman Slims Down Top Holdings in 4th Quarter
Summary: Bill Ackman ( Trades , Portfolio ), leader of Pershing Square Capital, has revealed his portfolio for the fourth quarter of 2020. The top five trades of the quarter were reductions made in Starbucks Corp. (NASDAQ:SBUX), Restaurant Brands International Inc. (NYSE:QSR), Lowe's Companies Inc. (NYSE:LOW), Agilent Technologies Inc. (NYSE:A) and Hilton Worldwide Holdings Inc. (NYSE:HLT). | -4 | A | 2021-02-13 to 2021-02-26 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-02-20 to 2021-02-26
[Next Week]: 2021-02-26 to 2021-03-05
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-02-26:
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
From 2021-02-20 to 2021-02-26, A's stock price decreased from 123.50 to 122.07. News during this period are listed below:
[News]:
- (2021-02-22 13:46) Agilent PD-L1 IHC 22C3 pharmDx Receives Expanded FDA Approval in Non-small Cell Lung Cancer (NSCLC)
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's PD-L1 IHC 22C3 pharmDx assay for expanded use in patients with non-small cell lung cancer (NSCLC). PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying NSCLC patients with tumor PD-L1 expression of Tumor Proportion Score (TPS) ≥ 50% for treatment with Libtayo® (cemiplimab-rwlc). This announcement underscores Agilent's co | -5 | A | 2021-02-20 to 2021-03-05 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-02-27 to 2021-03-05
[Next Week]: 2021-03-05 to 2021-03-12
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-03-05:
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
From 2021-02-27 to 2021-03-05, A's stock price decreased from 124.48 to 116.14. News during this period are listed below:
[News]:
- (2021-03-02 02:00) Agilent Announces Darlene Solomon Award Presented to University of Geneva Scientist Noemi Jiménez-Rojo
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the recipient of the 2021 Darlene Solomon Award is Noemi Jiménez-Rojo, a postdoctoral fellow studying membrane biology, lipid diversity, and function at the University of Geneva. The award was presented at a virtual ceremony during the International Singapore Lipid Symposium (iSLS) being held March 1-5 in Singapore. “Multidisciplinary approaches that include mass spectrometry will be crucial in the fo
- (2021-03-02 08:00) Agilent to Acquire Resolution Bioscience, Strengthening Leadership Position in Cancer Diagnostics
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Growth--Agilent to acquire Resolution Bioscience, strengthening leadership position in cancer diagnostics.
- (2021-03-03 08:40) Agilent Technologies Announces Proposed Offering of Senior Notes
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies announces proposed offering of senior notes.
- (2021-03-03 17:56) Agilent Technologies Announces Pricing of $850 Million of Senior Notes
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies announces pricing of $850 million of senior notes. | 5 | A | 2021-02-27 to 2021-03-12 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-03-06 to 2021-03-12
[Next Week]: 2021-03-12 to 2021-03-19
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-03-12:
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
From 2021-03-06 to 2021-03-12, A's stock price increased from 116.08 to 121.44. News during this period are listed below:
[News]:
- (2021-03-09 08:00) Agilent Completes CE-IVD Registration of qRT-PCR In Vitro Diagnostic Kit for SARS-CoV-2 RNA Detection
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit for the detection of SARS-CoV-2 RNA. The CE-IVD mark is in accordance with the European Union In Vitro Diagnostic Directive 98/79/EC and is available for immediate distribution. The Agilent SARS-CoV-2 qRT-PCR Dx kit is a real-time reverse transcriptase PCR (qRT-PCR) IVD reagent kit for the detection of SARS-CoV-2 RNA. Agilent's
- (2021-03-09 12:07) Dr. Katharine Knobil Named Agilent's First Chief Medical Officer
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent names Dr. Kate Knobil as the company's first chief medical officer. | 1 | A | 2021-03-06 to 2021-03-19 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-03-13 to 2021-03-19
[Next Week]: 2021-03-19 to 2021-03-26
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-03-19:
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
From 2021-03-13 to 2021-03-19, A's stock price decreased from 124.04 to 122.69. News during this period are listed below:
[News]:
- (2021-03-16 09:51) Agilent (A) Boosts Intelligence Capability With a New Launch
Summary: Agilent (A) unveils 8697 Headspace Sampler which unprecedented precision and strong connections.
- (2021-03-17 16:05) Agilent Announces Cash Dividend of 19.4 Cents per Share
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent announces quarterly dividend.
- (2021-03-18 12:30) Why Is Agilent (A) Down 5.8% Since Last Earnings Report?
Summary: Agilent (A) reported earnings 30 days ago. What's next for the stock? | 2 | A | 2021-03-13 to 2021-03-26 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-03-20 to 2021-03-26
[Next Week]: 2021-03-26 to 2021-04-02
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-03-26:
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
From 2021-03-20 to 2021-03-26, A's stock price increased from 123.61 to 125.64. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 2 | A | 2021-03-20 to 2021-04-02 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-03-27 to 2021-04-02
[Next Week]: 2021-04-02 to 2021-04-09
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-04-02:
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
From 2021-03-27 to 2021-04-02, A's stock price increased from 125.42 to 127.69. News during this period are listed below:
[News]:
- (2021-03-29 16:39) Bill Ackman's Pershing Square 2020 Annual Letter to Shareholder
Summary: To the Shareholders of Pershing Square Holdings, Ltd.: 2020 was the best year in the 17-year history of Pershing Square.
- (2021-03-30 08:00) Agilent Awards Octagon Therapeutics with a Golden Ticket at LabCentral
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announces that Octagon Therapeutics has been awarded an Agilent Golden Ticket at LabCentral. The Golden Ticket was presented to Octagon during a virtual online event on March 24 and provides funding for one scientist's lab bench space for a year, including the benefit of LabCentral's shared infrastructure and services. The three semi-finalists, Octagon Therapeutics, Rizana Therapeutics, and Nuakea Therapeutics presented c
- (2021-03-31 06:00) Oxford BioDynamics signs supply and resale agreement with Agilent Technologies, and launches EpiSwitch® Explorer Array Kit for R&D use
Summary: OXFORD, England--(BUSINESS WIRE)--Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch® 3D genomics platform, and Agilent Technologies (NYSE: A), a global leader in the life sciences, diagnostics, and applied chemical markets, have signed a supply and resale agreement for the manufacture and sale of the new EpiSwitch® Explorer Array Kit (“Kit”). Under the terms of the agreement, Agilent wil
- (2021-03-31 18:47) Agilent Leveraged To Post-Pandemic Recovery And Advanced Drug Discovery And Production
Summary: Agilent isn't a conventionally cheap stock, but should offer above-average revenue growth and margin expansion over the next five to 10 years, with leverage to several growth segments with biopharma. Agilent has been gaining share in instruments and demand should improve as lab activities and budgets normalize after the pandemic, with automation a longer-term growth driver. | 3 | A | 2021-03-27 to 2021-04-09 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-04-03 to 2021-04-09
[Next Week]: 2021-04-09 to 2021-04-16
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-04-09:
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
From 2021-04-03 to 2021-04-09, A's stock price increased from 130.00 to 131.91. News during this period are listed below:
[News]:
- (2021-04-08 12:52) Agilent (A) Moves to Strong Buy: Rationale Behind the Upgrade
Summary: Agilent (A) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. | 2 | A | 2021-04-03 to 2021-04-16 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-04-10 to 2021-04-16
[Next Week]: 2021-04-16 to 2021-04-23
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-04-16:
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
From 2021-04-10 to 2021-04-16, A's stock price increased from 131.27 to 134.58. News during this period are listed below:
[News]:
- (2021-04-13 20:00) Agilent Named One of Singapore's Best Employers
Summary: SINGAPORE--(BUSINESS WIRE)--Agilent Technologies announced that Agilent Singapore has been recognized as one of Singapore's Best Employers in 2021 for the second year-in-a-row.
- (2021-04-15 16:05) Agilent Completes Acquisition of Resolution Bioscience, Expands Role in Fast-growing NGS Market for Precision Oncology
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent completes acquisition of Resolution Bioscience. | 2 | A | 2021-04-10 to 2021-04-23 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-04-17 to 2021-04-23
[Next Week]: 2021-04-23 to 2021-04-30
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-04-23:
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
Quarter ending 2020-04-30 (FY 2020 Q2, currency: USD):
- Profitability: net margin 8.2%, operating margin 8.2%.
- Valuation: P/E 58.6x, P/B 5.0x, P/S 19.1x, P/FCF 84.6x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 1.63, quick ratio 1.24, cash ratio 0.68.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 25.3%, FCF / OCF 89.5%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
From 2021-04-17 to 2021-04-23, A's stock price increased from 133.50 to 136.68. News during this period are listed below:
[News]:
- (2021-04-20 12:19) Agilent Named One of the Best U.S. Companies for Diversity for Third Straight Year
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies (NYSE: A) today was named one of the top U.S. companies for diversity, marking the third straight year it has been recognized for its commitment to fostering a diverse and inclusive workplace. Specifically, Agilent ranked No. 83 out of 500 companies on Forbes's 2021 list of America's Best Employers for Diversity. The rating was based on dimensions of diversity including gender, ethnicity, LGBTQ+, age, and the differently abled. Agilent | -2 | A | 2021-04-17 to 2021-04-30 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-04-24 to 2021-04-30
[Next Week]: 2021-04-30 to 2021-05-07
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-04-30:
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
From 2021-04-24 to 2021-04-30, A's stock price decreased from 137.34 to 133.64. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 0 | A | 2021-04-24 to 2021-05-07 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-05-01 to 2021-05-07
[Next Week]: 2021-05-07 to 2021-05-14
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-05-07:
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
From 2021-05-01 to 2021-05-07, A's stock price increased from 133.19 to 133.90. News during this period are listed below:
[News]:
- (2021-05-03 15:00) Agilent to Webcast Second-Quarter Fiscal Year 2021 Financial Results Presentation
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent to announce fiscal second quarter financial results on May 25.
- (2021-05-06 16:41) 5 Cheap Growth Stocks for Q2 2021
Summary: After a brief selloff in Q1 2021, growth stocks are once again in focus. Investors can take advantage of this by investing in growth companies trading at low valuations.
- (2021-05-07 08:16) 6 Must-Buy Stocks Ahead of Earnings Results This Month
Summary: We have narrowed down our search to six major stocks likely to gain on earnings results. These are TGT, RL, KSS, NVDA, HPQ and A. | -2 | A | 2021-05-01 to 2021-05-14 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-05-08 to 2021-05-14
[Next Week]: 2021-05-14 to 2021-05-21
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-05-14:
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
From 2021-05-08 to 2021-05-14, A's stock price decreased from 131.87 to 131.15. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 1 | A | 2021-05-08 to 2021-05-21 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-05-15 to 2021-05-21
[Next Week]: 2021-05-21 to 2021-05-28
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-05-21:
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
- 2020-05-21: EPS actual 0.71 / estimate 0.58 / surprise +0.13 | revenue actual 1238000000 / estimate 1806262295 / surprise -568262295
From 2021-05-15 to 2021-05-21, A's stock price increased from 130.11 to 132.30. News during this period are listed below:
[News]:
- (2021-05-18 15:47) Agilent Technologies (A) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Summary: Agilent (A) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- (2021-05-19 16:05) Agilent Announces Cash Dividend of 19.4 Cents per Share
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent announces quarterly dividend.
- (2021-05-20 13:12) Agilent to Present at Jefferies Virtual Healthcare Conference
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #A--Agilent to present at Jefferies Virtual Healthcare Conference June 1.
- (2021-05-20 14:17) Agilent (A) to Report Q2 Earnings: What's in the Offing?
Summary: Agilent's (A) fiscal second-quarter results are expected to reflect portfolio strength and end-market momentum. | 4 | A | 2021-05-15 to 2021-05-28 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-05-22 to 2021-05-28
[Next Week]: 2021-05-28 to 2021-06-04
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-05-28:
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
From 2021-05-22 to 2021-05-28, A's stock price increased from 133.34 to 138.13. News during this period are listed below:
[News]:
- (2021-05-24 10:05) Earnings Outlook For Agilent Technologies
Summary: Agilent Technologies (NYSE:A) unveils its next round of earnings this Tuesday, May 25. Here is Benzinga's everything-that-matters guide for the earnings announcement.
- (2021-05-25 15:49) Company Profile for MedLab Diagnostics, LLC (DBA FastLabs)
Summary: --(BUSINESS WIRE)--FastLabs is a leading medical diagnostics company that provides rapid and accurate laboratory and medical testing for easy, safe, and quick lab results. Currently focused on COVID testing and other viruses, FastLabs provides express results for those that need fast PCR and rapid testing from the convenience of their vehicles, businesses or homes. With results in minutes, accessibility to fast, reliable and advanced technologies for accurate viral detection is FastLabs’ strongpoint in the effort to help expedite diagnosis, treatment and mitigate the spread of disease. Company: MedLab Diagnostics, LLC (DBA FastLabs) Headquarters Address: 7901 4th ST N STE 4000 ST. Petersburg, FL 33702 Main Telephone: 305 741 2655 Type of Organization: Private Industry: Health Key Executives: Vice President of Sales and Marketing: Nathalie Gil Sr. VP of Finance: Contact: Julieta Radiche Phone: 305 741 2655 Email: jradiche@fastlabsmed.com
- (2021-05-25 16:05) Agilent Reports Second-Quarter Fiscal Year 2021 Financial Results
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent announces second quarter financial results; raises full-year guidance.
- (2021-05-25 16:20) Recap: Agilent Technologies Q2 Earnings
Summary: Shares of Agilent Technologies (NYSE:A) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 36.62% over the past year to $0.97, which beat the estimate of $0.83.
- (2021-05-25 23:27) Agilent Technologies Inc. (A) CEO Mike McMullen on Q2 2021 Results - Earnings Call Transcript
Summary: Agilent Technologies Inc. (A) CEO Mike McMullen on Q2 2021 Results - Earnings Call Transcript
- (2021-05-26 08:53) What 12 Analyst Ratings Have To Say About Agilent Technologies
Summary: Analysts have provided the following ratings for Agilent Technologies (NYSE:A) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 0 0 1 Somewhat Bullish 4 0 0 0 Indifferent 0 0 0 0 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 In the last 3 months, 12 analysts have offered 12-month price targets for Agilent Technologies. The company has an average price target of $145.08 with a high of $160.00 and a low of $135.00.
- (2021-05-26 09:01) Agilent (A) Q2 Earnings & Revenues Beat Estimates, Rise Y/Y
Summary: Agilent's (A) fiscal second-quarter results benefit from strength across all geographical regions and end-market momentum.
- (2021-05-27 18:25) Agilent's 4th Consecutive Beat on Earnings Boosts Stock
Summary: On the heels of a bang-up second quarter, Agilent Technologies Inc. (A) shares climbed more than 3% to $137.58 on Thursday. The Santa Clara, California-based provider of application-focused solutions to the life sciences, diagnostics and applied chemical markets has beaten earnings estimates in each of the past four quarters. | 0 | A | 2021-05-22 to 2021-06-04 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-05-29 to 2021-06-04
[Next Week]: 2021-06-04 to 2021-06-11
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-06-04:
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
From 2021-05-29 to 2021-06-04, A's stock price increased from 137.20 to 137.90. News during this period are listed below:
[News]:
- (2021-06-01 08:00) Agilent Presents Thought Leader Award to Professor Chris Elliott
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Chris Elliott has received an Agilent Thought Leader Award. Dr. Elliott is Professor of Food Safety in the School of Biological Sciences and founder of the Institute for Global Food Security (IGFS) at Queen's University Belfast in Northern Ireland. The award recognizes his contributions to the field of food authenticity and the development of novel approaches to the detection of food fraud. Professor
- (2021-06-01 08:45) Agilent: Expensive, Yet Safe Bet
Summary: Agilent has been a stealth value-creating play over the past years.
- (2021-06-02 08:00) Agilent Announces New SureSelect Human All Exon V8
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of SureSelect Human All Exon V8 – a new exome design that provides comprehensive content and up-to-date coverage of protein coding regions from RefSeq, CCDS, and GENCODE. It also covers the TERT promoter and hard-to-capture exons that are omitted by other exomes on the market. The new design is available in three options – routine exome sequencing (Exome v8), clinical research sequencing (v8 Cl
- (2021-06-04 08:00) Cell-Free DNA Guided Targeted Therapy Leads to Better Survival in Advanced Non-Small Cell Lung Cancer
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a presentation by Memorial Sloan Kettering Cancer Center (MSK) at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) to discuss the Resolution ctDx Lung, a laboratory-developed test (LDT) developed by Resolution Bioscience. The presentation titled Overall survival with circulating tumor DNA-guided therapy in advanced non-small cell lung cancer will present evidence for the clin | 4 | A | 2021-05-29 to 2021-06-11 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-06-05 to 2021-06-11
[Next Week]: 2021-06-11 to 2021-06-18
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-06-11:
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
From 2021-06-05 to 2021-06-11, A's stock price increased from 137.65 to 143.53. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 1 | A | 2021-06-05 to 2021-06-18 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-06-12 to 2021-06-18
[Next Week]: 2021-06-18 to 2021-06-25
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-06-18:
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
From 2021-06-12 to 2021-06-18, A's stock price increased from 144.39 to 145.01. News during this period are listed below:
[News]:
- (2021-06-14 08:00) Agilent Presents Thought Leader Award to Dr. Stéphane Bayen
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Stéphane Bayen has received an Agilent Thought Leader Award. Dr. Bayen is an Associate Professor in the Department of Food Science and Agricultural Chemistry at McGill University in Montreal, Quebec, Canada. The award will support Dr. Bayen's research contributions to analytical techniques and the development of reliable and robust workflows to identify honey authenticity using non-targeted chemical f
- (2021-06-14 13:32) Surging Earnings Estimates Signal Upside for Agilent (A) Stock
Summary: Agilent (A) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- (2021-06-17 12:02) Is Agilent Technologies (A) Stock Outpacing Its Computer and Technology Peers This Year?
Summary: Is (A) Outperforming Other Computer and Technology Stocks This Year?
- (2021-06-18 09:47) New to Investing? This 1 Computer and Technology Stock Could Be the Perfect Starting Point
Summary: Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service. | 2 | A | 2021-06-12 to 2021-06-25 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-06-19 to 2021-06-25
[Next Week]: 2021-06-25 to 2021-07-02
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-06-25:
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
From 2021-06-19 to 2021-06-25, A's stock price increased from 146.41 to 147.28. News during this period are listed below:
[News]:
- (2021-06-22 03:00) Agilent Completes the InfinityLab Bio LC Portfolio
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of three InfinityLab Bio LC systems specifically developed to meet the needs of the biopharma industry. The release is central to the Agilent portfolio of complete Bio LC solutions, featuring instruments, columns, and supplies that seamlessly integrate with Agilent OpenLab and MassHunter software, and CrossLab services to maximize efficiency in biopharma labs. The three new systems include the 1
- (2021-06-23 11:17) Agilent (A) Expands Presence in LC Market With New Systems
Summary: Agilent (A) expands its Bio Liquid Chromatography solutions portfolio with three new systems to fulfil the needs of biopharma industry. | 1 | A | 2021-06-19 to 2021-07-02 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-06-26 to 2021-07-02
[Next Week]: 2021-07-02 to 2021-07-09
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-07-02:
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
From 2021-06-26 to 2021-07-02, A's stock price increased from 147.93 to 148.82. News during this period are listed below:
[News]:
- (2021-06-28 08:00) Resolution Bioscience (a part of Agilent) Investigated Acquired Resistance to KRAS G12C Inhibition
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the publication of a study carried out in partnership with Resolution Bioscience (a part of Agilent) and Dana-Farber Cancer Institute. The paper was published in the New England Journal of Medicine (NEJM) on June 24 and is titled "Acquired Resistance to KRAS G12C Inhibition in Cancer." It demonstrates the clinical utility of liquid biopsy techniques to detect resistance to targeted therapies, including inh | 1 | A | 2021-06-26 to 2021-07-09 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-07-03 to 2021-07-09
[Next Week]: 2021-07-09 to 2021-07-16
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-07-09:
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
From 2021-07-03 to 2021-07-09, A's stock price increased from 148.98 to 150.03. News during this period are listed below:
[News]:
- (2021-07-05 11:16) Agilent Technologies (A) Boasts Earnings & Price Momentum: Should You Buy?
Summary: Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
- (2021-07-05 12:47) What Makes Agilent Technologies (A) a Strong Momentum Stock: Buy Now?
Summary: Does Agilent Technologies (A) have what it takes to be a top stock pick for momentum investors? Let's find out. | -1 | A | 2021-07-03 to 2021-07-16 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-07-10 to 2021-07-16
[Next Week]: 2021-07-16 to 2021-07-23
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-07-16:
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
From 2021-07-10 to 2021-07-16, A's stock price decreased from 149.51 to 148.93. News during this period are listed below:
[News]:
- (2021-07-13 09:00) MOBILion Systems Inc. Announces $60 Million Series C Financing Round Led by D1
Summary: CHADDS FORD, Pa., July 13, 2021 /PRNewswire/ -- MOBILion Systems Inc. , a pioneer in fast, efficient, highresolution instrumentation for biomarker discovery, diagnostics and biotherapeutic drug characterization, today announced the close of a $60 million Series C financing round. | 2 | A | 2021-07-10 to 2021-07-23 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-07-17 to 2021-07-23
[Next Week]: 2021-07-23 to 2021-07-30
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-07-23:
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
From 2021-07-17 to 2021-07-23, A's stock price increased from 147.58 to 152.31. News during this period are listed below:
[News]:
- (2021-07-20 08:30) Agilent Announces Optimized and Verified Method for Testing Over 100 PFAS Compounds
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the availability of an optimized and verified eMethod for PFAS Analysis in Water by LC/TQ for testing per- and polyfluoroalkyl substances (PFAS) in drinking and surface water using liquid chromatography and mass spectrometry. PFAS—known as ‘forever chemicals'—are a group of man-made chemicals that include PFOA, PFOS, GenX, and many others. PFAS have been manufactured and used in a variety of industries wor
- (2021-07-20 12:34) Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC)
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the company's PD-L1 IHC 22C3 pharmDx assay is now labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union. PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying NSCLC patients with tumor PD-L1 expression of Tumor Proportion Score (TPS) ≥ 50% for treatment with Libtayo® (cemiplimab). This announcement underscores Agilent's continuing commitment to th
- (2021-07-21 12:23) Agilent (A) Expands pharmDX Assay Use in the European Union
Summary: Agilent Technologies (A) expands the use of PD-L1 IHC 22C3 pharmDx assay for cancer treatment in the European Union. | 1 | A | 2021-07-17 to 2021-07-30 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-07-24 to 2021-07-30
[Next Week]: 2021-07-30 to 2021-08-06
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-07-30:
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
Quarter ending 2020-07-31 (FY 2020 Q3, currency: USD):
- Profitability: net margin 15.8%, operating margin 18.2%.
- Valuation: P/E 37.4x, P/B 6.0x, P/S 23.6x, P/FCF 112.3x.
- Balance sheet & liquidity: debt/equity 0.47, debt/assets 0.24, current ratio 2.47, quick ratio 1.90, cash ratio 1.03.
- Efficiency & cash flow: asset turnover 0.13x, OCF / sales 23.0%, FCF / OCF 91.4%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
From 2021-07-24 to 2021-07-30, A's stock price increased from 150.25 to 153.23. News during this period are listed below:
[News]:
- (2021-07-27 08:00) Clinical Utility of ALK Fusion Detection by Liquid Biopsy
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the publication of a paper in the journal Lung Cancer, titled "Clinical Utility of Next-Generation Sequencing-Based ctDNA Testing for Common and Novel ALK Fusions". The study, jointly published by Resolution Bioscience (now a part of Agilent) and Memorial Sloan Kettering Cancer Center (MSK), describes the use of plasma ctDNA NGS to detect novel anaplastic lymphoma kinase (ALK) fusions, and to serially moni
- (2021-07-30 12:55) 3 Stocks With Price and Earnings Estimate Momentum
Summary: 3 Stocks With Price and Earnings Estimate Momentum | 2 | A | 2021-07-24 to 2021-08-06 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-07-31 to 2021-08-06
[Next Week]: 2021-08-06 to 2021-08-13
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-08-06:
Quarter ending 2021-07-31 (FY 2021 Q3, currency: USD):
- Profitability: net margin 16.6%, operating margin 21.2%.
- Valuation: P/E 44.0x, P/B 9.4x, P/S 29.3x, P/FCF 166.4x.
- Balance sheet & liquidity: debt/equity 0.58, debt/assets 0.27, current ratio 2.11, quick ratio 1.63, cash ratio 0.83.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 21.1%, FCF / OCF 83.5%.
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
From 2021-07-31 to 2021-08-06, A's stock price increased from 153.07 to 155.70. News during this period are listed below:
[News]:
- (2021-08-02 13:43) Can Agilent (A) Keep the Earnings Surprise Streak Alive?
Summary: Agilent (A) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- (2021-08-02 13:43) Are You Looking for a Top Momentum Pick? Why Agilent Technologies (A) is a Great Choice
Summary: Does Agilent Technologies (A) have what it takes to be a top stock pick for momentum investors? Let's find out.
- (2021-08-03 08:20) Agilent Announces Target Enrichment Manufacturing Facility in China
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that is has established in-country manufacturing for its SureSelect portfolio at its facility in Hangzhou, China. Agilent is a leading provider of next-generation sequencing assays, and customers often develop custom panels for their routine applications. Therefore, delivery turnaround time is an essential aspect of how Agilent uniquely serves its customers, enabling them to validate and implement their as
- (2021-08-04 11:00) Agilent Earns 2021 Great Place to Work Certification in the U.S.
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent earns 2021 Great Place to Work certification in the U.S.
- (2021-08-06 06:54) 5 Corporate Giants to Buy Ahead of Earnings Results This Month
Summary: Five corporate bigwigs are slated to release their earnings results this month. These are: WMT, A, TGT, DE and ULTA. | 2 | A | 2021-07-31 to 2021-08-13 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-08-07 to 2021-08-13
[Next Week]: 2021-08-13 to 2021-08-20
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-08-13:
Quarter ending 2021-07-31 (FY 2021 Q3, currency: USD):
- Profitability: net margin 16.6%, operating margin 21.2%.
- Valuation: P/E 44.0x, P/B 9.4x, P/S 29.3x, P/FCF 166.4x.
- Balance sheet & liquidity: debt/equity 0.58, debt/assets 0.27, current ratio 2.11, quick ratio 1.63, cash ratio 0.83.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 21.1%, FCF / OCF 83.5%.
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
- 2020-08-18: EPS actual 0.78 / estimate 0.66 / surprise +0.12 | revenue actual 1261000000 / estimate 1291544964 / surprise -30544964
From 2021-08-07 to 2021-08-13, A's stock price increased from 156.54 to 159.23. News during this period are listed below:
[News]:
- (2021-08-10 16:17) Agilent Technologies (A) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Summary: Agilent (A) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | 6 | A | 2021-08-07 to 2021-08-20 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-08-14 to 2021-08-20
[Next Week]: 2021-08-20 to 2021-08-27
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-08-20:
Quarter ending 2021-07-31 (FY 2021 Q3, currency: USD):
- Profitability: net margin 16.6%, operating margin 21.2%.
- Valuation: P/E 44.0x, P/B 9.4x, P/S 29.3x, P/FCF 166.4x.
- Balance sheet & liquidity: debt/equity 0.58, debt/assets 0.27, current ratio 2.11, quick ratio 1.63, cash ratio 0.83.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 21.1%, FCF / OCF 83.5%.
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-08-17: EPS actual 1.10 / estimate 0.99 / surprise +0.11 | revenue actual 1586000000 / estimate 1659210000 / surprise -73210000
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
From 2021-08-14 to 2021-08-20, A's stock price increased from 162.07 to 168.13. News during this period are listed below:
[News]:
- (2021-08-16 11:26) Agilent (A) to Report Q3 Earnings: What's in the Cards?
Summary: Agilent's (A) fiscal third-quarter results are likely to reflect strength across its segments and product portfolio.
- (2021-08-17 16:05) Agilent Reports Third-Quarter Fiscal Year 2021 Financial Results
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent reports strong fiscal third quarter financial results, raises full-year guidance.
- (2021-08-17 16:37) Recap: Agilent Technologies Q3 Earnings
Summary: Shares of Agilent Technologies (NYSE:A) fell 0.6% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 41.03% year over year to $1.10, which beat the estimate of $0.99.
- (2021-08-17 20:08) Agilent Technologies, Inc. (A) CEO Mike McMullen on Q3 2021 Results - Earnings Call Transcript
Summary: Agilent Technologies, Inc. (A) CEO Mike McMullen on Q3 2021 Results - Earnings Call Transcript
- (2021-08-18 11:01) Agilent Stock Trading At 52-Week High As Analysts Beef Up Target Price After Q3 Earnings
Summary: Agilent Technologies Inc (NYSE: A) reported third-quarter revenue of $1.59 billion, +26% and up 21% on a core basis, slightly beating the consensus of $1.54 billion. During the third quarter, revenues for the diagnostic and genomics group (DGG) rose 44% to $346 million.
- (2021-08-18 12:15) Agilent (A) Q3 Earnings & Revenues Beat Estimates, Rise Y/Y
Summary: Agilent's (A) fiscal third-quarter results benefit from strength across all geographical regions, business groups and end-market momentum.
- (2021-08-19 08:00) Researchers Develop COVID-19 Severity Screening Method Based on the Agilent Cary 630 FTIR Spectrometer
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announces that researchers at the Indian Institute of Technology Bombay in India and the QIMR Berghofer Medical Research Institute in Australia have developed a rapid method for differentiating COVID-19-positive patients expected to show severe symptoms from those likely to experience only mild symptoms. The classification algorithm, published in the journal Analytical Chemistry, is based on infrared spectra of blood plas | 3 | A | 2021-08-14 to 2021-08-27 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-08-21 to 2021-08-27
[Next Week]: 2021-08-27 to 2021-09-03
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-08-27:
Quarter ending 2021-07-31 (FY 2021 Q3, currency: USD):
- Profitability: net margin 16.6%, operating margin 21.2%.
- Valuation: P/E 44.0x, P/B 9.4x, P/S 29.3x, P/FCF 166.4x.
- Balance sheet & liquidity: debt/equity 0.58, debt/assets 0.27, current ratio 2.11, quick ratio 1.63, cash ratio 0.83.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 21.1%, FCF / OCF 83.5%.
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-08-17: EPS actual 1.10 / estimate 0.99 / surprise +0.11 | revenue actual 1586000000 / estimate 1659210000 / surprise -73210000
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
From 2021-08-21 to 2021-08-27, A's stock price increased from 170.00 to 173.81. News during this period are listed below:
[News]:
- (2021-08-22 01:50) Agilent Technologies: Momentum In Genomics Keeps It Interesting
Summary: Agilent Technologies: Momentum In Genomics Keeps It Interesting
- (2021-08-23 11:00) Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Esophageal Cancer
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the company's PD-L1 IHC 22C3 pharmDx assay has expanded its use in Europe. The assay is now CE-IVD marked for use as an aid in identifying esophageal cancer patients for treatment with KEYTRUDA using Combined Positive Score (CPS) ≥ 10.1 In Europe, KEYTRUDA is approved in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with locally advanced unresectable or metastatic eso
- (2021-08-24 07:35) Goldman Sachs Boosts Price Targets on 4 Strong Buy-Rated Stocks
Summary: With August almost over and the back-to-school season upon us, the lion's share of the outstanding second-quarter earnings results have been posted, and analysts and investors on Wall Street are very satisfied with the results.
- (2021-08-24 18:30) Ackman committed to finding a deal for PSTH; sold Agilent to raise cash
Summary: Billionaire investor William Ackman, who last year launched the biggest-ever special-purpose acquisition company, said on Tuesday he remains committed to finding a merger partner for his blank-check company Pershing Square Tontine Holdings Ltd (PSTH). | 3 | A | 2021-08-21 to 2021-09-03 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-08-28 to 2021-09-03
[Next Week]: 2021-09-03 to 2021-09-10
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-09-03:
Quarter ending 2021-07-31 (FY 2021 Q3, currency: USD):
- Profitability: net margin 16.6%, operating margin 21.2%.
- Valuation: P/E 44.0x, P/B 9.4x, P/S 29.3x, P/FCF 166.4x.
- Balance sheet & liquidity: debt/equity 0.58, debt/assets 0.27, current ratio 2.11, quick ratio 1.63, cash ratio 0.83.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 21.1%, FCF / OCF 83.5%.
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-08-17: EPS actual 1.10 / estimate 0.99 / surprise +0.11 | revenue actual 1586000000 / estimate 1659210000 / surprise -73210000
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
From 2021-08-28 to 2021-09-03, A's stock price increased from 176.73 to 179.28. News during this period are listed below:
[News]:
- (2021-09-01 10:45) Agilent Technologies (A) Boasts Earnings & Price Momentum: Should You Buy?
Summary: Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
- (2021-09-01 11:00) Agilent to Present at Wells Fargo Virtual Healthcare Conference
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent to present at 2021 Wells Fargo Virtual Healthcare Conference.
- (2021-09-02 08:00) Agilent and Visiopharm Expand Collaboration with Worldwide Distribution Agreement
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the signing of a worldwide distribution agreement with Visiopharm, enabling Agilent to co-market Visiopharm's portfolio of CE-IVD marked artificial intelligence (AI)-driven precision pathology software in addition to Agilent's portfolio of automated pathology staining solutions. With an initial focus on Europe, this agreement marks Agilent's first entry into the growing digital pathology market and strengt
- (2021-09-03 12:30) 3 Stocks Growing Free Cash Flow Fast
Summary: If you are screening the market for investment opportunities among U.S.-listed equities, you may want to consider the stocks listed below, as they have seen their free cash flow (FCF) grow notably over recent years. As a result, these businesses should be flexible enough to continue to support the development of projects and return cash to shareholders.
- (2021-09-03 13:00) Has Agilent Technologies (A) Outpaced Other Computer and Technology Stocks This Year?
Summary: Is (A) Outperforming Other Computer and Technology Stocks This Year?
- (2021-09-03 13:45) Agilent (A), Visiopharm Unite for Supply of Pathology Solutions
Summary: Agilent (A) signs an agreement with Visiopharm to globally distribute their pathology solutions. | -1 | A | 2021-08-28 to 2021-09-10 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-09-04 to 2021-09-10
[Next Week]: 2021-09-10 to 2021-09-17
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-09-10:
Quarter ending 2021-07-31 (FY 2021 Q3, currency: USD):
- Profitability: net margin 16.6%, operating margin 21.2%.
- Valuation: P/E 44.0x, P/B 9.4x, P/S 29.3x, P/FCF 166.4x.
- Balance sheet & liquidity: debt/equity 0.58, debt/assets 0.27, current ratio 2.11, quick ratio 1.63, cash ratio 0.83.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 21.1%, FCF / OCF 83.5%.
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-08-17: EPS actual 1.10 / estimate 0.99 / surprise +0.11 | revenue actual 1586000000 / estimate 1659210000 / surprise -73210000
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
From 2021-09-04 to 2021-09-10, A's stock price decreased from 177.72 to 177.23. News during this period are listed below:
[News]:
- (2021-09-07 08:00) Agilent Announces Thought Leader Award to David R. Liu at the Broad Institute
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced Dr. David R. Liu has been selected to receive a prestigious Agilent Thought Leader Award. A prominent researcher in the field of genome editing, Dr. Liu is Professor and Director of the Merkin Institute of Transformative Technologies in Healthcare, Vice-Chair of the Faculty at the Broad Institute of MIT and Harvard, Professor of Natural Sciences and Professor of Chemistry and Chemical Biology at Harvard Un | -2 | A | 2021-09-04 to 2021-09-17 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-09-11 to 2021-09-17
[Next Week]: 2021-09-17 to 2021-09-24
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-09-17:
Quarter ending 2021-07-31 (FY 2021 Q3, currency: USD):
- Profitability: net margin 16.6%, operating margin 21.2%.
- Valuation: P/E 44.0x, P/B 9.4x, P/S 29.3x, P/FCF 166.4x.
- Balance sheet & liquidity: debt/equity 0.58, debt/assets 0.27, current ratio 2.11, quick ratio 1.63, cash ratio 0.83.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 21.1%, FCF / OCF 83.5%.
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-08-17: EPS actual 1.10 / estimate 0.99 / surprise +0.11 | revenue actual 1586000000 / estimate 1659210000 / surprise -73210000
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
From 2021-09-11 to 2021-09-17, A's stock price increased from 172.08 to 173.94. News during this period are listed below:
[News]:
- (2021-09-17 10:42) New to Investing? This 1 Computer and Technology Stock Could Be the Perfect Starting Point
Summary: Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service. | -1 | A | 2021-09-11 to 2021-09-24 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-09-18 to 2021-09-24
[Next Week]: 2021-09-24 to 2021-10-01
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-09-24:
Quarter ending 2021-07-31 (FY 2021 Q3, currency: USD):
- Profitability: net margin 16.6%, operating margin 21.2%.
- Valuation: P/E 44.0x, P/B 9.4x, P/S 29.3x, P/FCF 166.4x.
- Balance sheet & liquidity: debt/equity 0.58, debt/assets 0.27, current ratio 2.11, quick ratio 1.63, cash ratio 0.83.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 21.1%, FCF / OCF 83.5%.
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-08-17: EPS actual 1.10 / estimate 0.99 / surprise +0.11 | revenue actual 1586000000 / estimate 1659210000 / surprise -73210000
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
From 2021-09-18 to 2021-09-24, A's stock price increased from 171.34 to 172.40. News during this period are listed below:
[News]:
- (2021-09-22 16:05) Agilent Announces Cash Dividend of 19.4 Cents per Share
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent announces dividend.
- (2021-09-23 16:05) Dr. Mikael Dolsten Named to Agilent Board of Directors
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Pfizer executive Dr. Mikael Dolsten appointed to Agilent board of directors. | -10 | A | 2021-09-18 to 2021-10-01 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-09-25 to 2021-10-01
[Next Week]: 2021-10-01 to 2021-10-08
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-10-01:
Quarter ending 2021-07-31 (FY 2021 Q3, currency: USD):
- Profitability: net margin 16.6%, operating margin 21.2%.
- Valuation: P/E 44.0x, P/B 9.4x, P/S 29.3x, P/FCF 166.4x.
- Balance sheet & liquidity: debt/equity 0.58, debt/assets 0.27, current ratio 2.11, quick ratio 1.63, cash ratio 0.83.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 21.1%, FCF / OCF 83.5%.
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-08-17: EPS actual 1.10 / estimate 0.99 / surprise +0.11 | revenue actual 1586000000 / estimate 1659210000 / surprise -73210000
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
From 2021-09-25 to 2021-10-01, A's stock price decreased from 166.38 to 155.99. News during this period are listed below:
[News]:
- (2021-09-26 02:57) Dividend Champion And Contender Highlights: Week Of September 26
Summary: A weekly summary of dividend activity for Dividend Champions and Contenders.
- (2021-09-28 08:00) Agilent Announces Thought Leader Award to Bernhard Lendl at the TU Wien (Vienna)
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced Professor Bernhard Lendl has been selected to receive a prestigious Agilent Thought Leader Award. Highly renowned in the field of vibrational spectroscopy, Dr. Lendl is a professor at the TU Wien (Vienna) and head of the working group on Process Analysis & Vibrational Spectroscopy at the institution. Professor Lendl's work focuses on adapting powerful spectroscopic techniques and unique combinations of | -2 | A | 2021-09-25 to 2021-10-08 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-10-02 to 2021-10-08
[Next Week]: 2021-10-08 to 2021-10-15
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-10-08:
Quarter ending 2021-07-31 (FY 2021 Q3, currency: USD):
- Profitability: net margin 16.6%, operating margin 21.2%.
- Valuation: P/E 44.0x, P/B 9.4x, P/S 29.3x, P/FCF 166.4x.
- Balance sheet & liquidity: debt/equity 0.58, debt/assets 0.27, current ratio 2.11, quick ratio 1.63, cash ratio 0.83.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 21.1%, FCF / OCF 83.5%.
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-08-17: EPS actual 1.10 / estimate 0.99 / surprise +0.11 | revenue actual 1586000000 / estimate 1659210000 / surprise -73210000
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
From 2021-10-02 to 2021-10-08, A's stock price remained roughly flat from 152.36 to 152.47. News during this period are listed below:
[News]:
No relevant company news reported during this week. | 1 | A | 2021-10-02 to 2021-10-15 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-10-09 to 2021-10-15
[Next Week]: 2021-10-15 to 2021-10-22
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-10-15:
Quarter ending 2021-07-31 (FY 2021 Q3, currency: USD):
- Profitability: net margin 16.6%, operating margin 21.2%.
- Valuation: P/E 44.0x, P/B 9.4x, P/S 29.3x, P/FCF 166.4x.
- Balance sheet & liquidity: debt/equity 0.58, debt/assets 0.27, current ratio 2.11, quick ratio 1.63, cash ratio 0.83.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 21.1%, FCF / OCF 83.5%.
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-08-17: EPS actual 1.10 / estimate 0.99 / surprise +0.11 | revenue actual 1586000000 / estimate 1659210000 / surprise -73210000
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
From 2021-10-09 to 2021-10-15, A's stock price increased from 150.02 to 153.27. News during this period are listed below:
[News]:
- (2021-10-13 16:16) Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer (EBC) at high risk of disease recurrence, for whom adjuvant treatment with Verzenio® (abemaciclib) in combination with endocrine therapy is being considered. This is the first IHC assay measuring Ki-67 expression to receive FDA approval in the context of treatment with Verzenio and was de | 3 | A | 2021-10-09 to 2021-10-22 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-10-16 to 2021-10-22
[Next Week]: 2021-10-22 to 2021-10-29
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-10-22:
Quarter ending 2021-07-31 (FY 2021 Q3, currency: USD):
- Profitability: net margin 16.6%, operating margin 21.2%.
- Valuation: P/E 44.0x, P/B 9.4x, P/S 29.3x, P/FCF 166.4x.
- Balance sheet & liquidity: debt/equity 0.58, debt/assets 0.27, current ratio 2.11, quick ratio 1.63, cash ratio 0.83.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 21.1%, FCF / OCF 83.5%.
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-08-17: EPS actual 1.10 / estimate 0.99 / surprise +0.11 | revenue actual 1586000000 / estimate 1659210000 / surprise -73210000
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
From 2021-10-16 to 2021-10-22, A's stock price increased from 154.78 to 157.97. News during this period are listed below:
[News]:
- (2021-10-20 11:40) ETFs to Ride on a Solid Start to Q3 Earnings
Summary: The rounds of upbeat earnings has set the stage for the S&P 500 Index to hit new highs as more Q3 earnings unfold.
- (2021-10-21 08:31) Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers. Gastric (stomach) cancer is the fifth most common cancer and the fourth leading cause of cancer death worldwide, with over 1,000,000 new cases and approximately 770,000 deaths | 0 | A | 2021-10-16 to 2021-10-29 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-10-23 to 2021-10-29
[Next Week]: 2021-10-29 to 2021-11-05
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-10-29:
Quarter ending 2021-07-31 (FY 2021 Q3, currency: USD):
- Profitability: net margin 16.6%, operating margin 21.2%.
- Valuation: P/E 44.0x, P/B 9.4x, P/S 29.3x, P/FCF 166.4x.
- Balance sheet & liquidity: debt/equity 0.58, debt/assets 0.27, current ratio 2.11, quick ratio 1.63, cash ratio 0.83.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 21.1%, FCF / OCF 83.5%.
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
Quarter ending 2020-10-31 (FY 2020 Q4, currency: USD):
- Profitability: net margin 15.0%, operating margin 20.2%.
- Valuation: P/E 35.4x, P/B 6.5x, P/S 21.2x, P/FCF 89.8x.
- Balance sheet & liquidity: debt/equity 0.48, debt/assets 0.25, current ratio 2.33, quick ratio 1.84, cash ratio 0.98.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 25.4%, FCF / OCF 92.8%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-08-17: EPS actual 1.10 / estimate 0.99 / surprise +0.11 | revenue actual 1586000000 / estimate 1659210000 / surprise -73210000
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
From 2021-10-23 to 2021-10-29, A's stock price decreased from 158.34 to 157.49. News during this period are listed below:
[News]:
- (2021-10-26 08:05) Agilent Announced as My Green Lab's First 'Transformative Level' Sponsor and First Sponsor of the My Green Lab Certification Program
Summary: SANTA CLARA, Calif., Oct. 26, 2021 /PRNewswire/ -- Agilent Technologies Inc. (NYSE: A) announced today that it has undertaken the highest sponsorship level of My Green Lab —Transformative Level—as the first institution to do so.
- (2021-10-27 07:45) ECLUSIVE: Agilent Commits to Net-Zero Greenhouse Gas Emissions By 2050
Summary: Agilent Technologies Inc (NYSE: A) has committed to achieving net-zero greenhouse gas emissions no later than 2050. Agilent has also committed to interim greenhouse gas reduction targets.
- (2021-10-27 08:00) Agilent Commits to Net-Zero Greenhouse Gas Emissions by 2050
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent Technologies, Inc. (NYSE: A) today announced its commitment to achieve net-zero greenhouse gas emissions no later than 2050. The commitment adds to the global effort by governments, corporations, and other institutions to limit warming of the climate to 1.5°C above pre-industrial levels, a goal of the 2015 Paris Agreement on climate change. To ensure the company achieves its net-zero goals, Agilent has also committed to interim greenhouse gas reduct | -1 | A | 2021-10-23 to 2021-11-05 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-10-30 to 2021-11-05
[Next Week]: 2021-11-05 to 2021-11-12
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-11-05:
Quarter ending 2021-10-31 (FY 2021 Q4, currency: USD):
- Profitability: net margin 26.6%, operating margin 23.8%.
- Valuation: P/E 26.9x, P/B 8.8x, P/S 28.7x, P/FCF 125.6x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 2.22, quick ratio 1.74, cash ratio 0.87.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 26.6%, FCF / OCF 85.9%.
Quarter ending 2021-07-31 (FY 2021 Q3, currency: USD):
- Profitability: net margin 16.6%, operating margin 21.2%.
- Valuation: P/E 44.0x, P/B 9.4x, P/S 29.3x, P/FCF 166.4x.
- Balance sheet & liquidity: debt/equity 0.58, debt/assets 0.27, current ratio 2.11, quick ratio 1.63, cash ratio 0.83.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 21.1%, FCF / OCF 83.5%.
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-08-17: EPS actual 1.10 / estimate 0.99 / surprise +0.11 | revenue actual 1586000000 / estimate 1659210000 / surprise -73210000
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
From 2021-10-30 to 2021-11-05, A's stock price decreased from 157.06 to 156.41. News during this period are listed below:
[News]:
- (2021-10-31 15:35) Stocks This Week: Buy ProShares Ultra QQQ And Agilent Technologies
Summary: Here are trading recommendations for this coming strong week.
- (2021-11-01 08:06) Agilent Announces New Ion Mobility LC/Q-TOF and Enhanced Solutions for Biotherapeutics at ASMS 2021
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today the new Agilent 6560C Ion Mobility LC/Q-TOF, enhancements to the VWorks automation software suite, and new AssayMAP large capacity cartridges. These solutions will be on show at the American Society for Mass Spectrometry Conference (ASMS) which is being held October 31 - November 4, 2021, in Philadelphia, PA. These products improve the analysis of proteins and peptides to speed up the development of new pr
- (2021-11-01 13:49) Why the Earnings Surprise Streak Could Continue for Agilent (A)
Summary: Agilent (A) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- (2021-11-02 14:00) Agilent Names John Palma to Lead Global Medical Affairs Organization
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent has named John Palma vice president of Medical Affairs. | 3 | A | 2021-10-30 to 2021-11-12 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-11-06 to 2021-11-12
[Next Week]: 2021-11-12 to 2021-11-19
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-11-12:
Quarter ending 2021-10-31 (FY 2021 Q4, currency: USD):
- Profitability: net margin 26.6%, operating margin 23.8%.
- Valuation: P/E 26.9x, P/B 8.8x, P/S 28.7x, P/FCF 125.6x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 2.22, quick ratio 1.74, cash ratio 0.87.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 26.6%, FCF / OCF 85.9%.
Quarter ending 2021-07-31 (FY 2021 Q3, currency: USD):
- Profitability: net margin 16.6%, operating margin 21.2%.
- Valuation: P/E 44.0x, P/B 9.4x, P/S 29.3x, P/FCF 166.4x.
- Balance sheet & liquidity: debt/equity 0.58, debt/assets 0.27, current ratio 2.11, quick ratio 1.63, cash ratio 0.83.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 21.1%, FCF / OCF 83.5%.
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-08-17: EPS actual 1.10 / estimate 0.99 / surprise +0.11 | revenue actual 1586000000 / estimate 1659210000 / surprise -73210000
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
From 2021-11-06 to 2021-11-12, A's stock price remained roughly flat from 160.94 to 160.88. News during this period are listed below:
[News]:
- (2021-11-09 19:49) Agilent Technologies (A) Dips More Than Broader Markets: What You Should Know
Summary: Agilent Technologies (A) closed the most recent trading day at $159.81, moving -0.7% from the previous trading session. | 2 | A | 2021-11-06 to 2021-11-19 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-11-13 to 2021-11-19
[Next Week]: 2021-11-19 to 2021-11-26
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-11-19:
Quarter ending 2021-10-31 (FY 2021 Q4, currency: USD):
- Profitability: net margin 26.6%, operating margin 23.8%.
- Valuation: P/E 26.9x, P/B 8.8x, P/S 28.7x, P/FCF 125.6x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 2.22, quick ratio 1.74, cash ratio 0.87.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 26.6%, FCF / OCF 85.9%.
Quarter ending 2021-07-31 (FY 2021 Q3, currency: USD):
- Profitability: net margin 16.6%, operating margin 21.2%.
- Valuation: P/E 44.0x, P/B 9.4x, P/S 29.3x, P/FCF 166.4x.
- Balance sheet & liquidity: debt/equity 0.58, debt/assets 0.27, current ratio 2.11, quick ratio 1.63, cash ratio 0.83.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 21.1%, FCF / OCF 83.5%.
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-08-17: EPS actual 1.10 / estimate 0.99 / surprise +0.11 | revenue actual 1586000000 / estimate 1659210000 / surprise -73210000
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
- 2020-11-23: EPS actual 0.98 / estimate 0.91 / surprise +0.07 | revenue actual 1483000000 / estimate 1817870967 / surprise -334870967
From 2021-11-13 to 2021-11-19, A's stock price increased from 157.78 to 164.30. News during this period are listed below:
[News]:
- (2021-11-15 09:08) Second Half Of November Brings Dividend Increases From Merck, Nike And 12 Others
Summary: Investors saw a few very good dividend increases in the first half of November, with ADP, Snap-on, and Roper Technologies announcing double-digit boosts, and a massive 29% boost from HP. The second half of November will bring double-digit boosts from a few more companies including Nike, Motorola Solutions, Aflac, and Agilent Technologies.
- (2021-11-15 16:11) Agilent Technologies (A) Reports Next Week: Wall Street Expects Earnings Growth
Summary: Agilent (A) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- (2021-11-16 10:45) 4 Top Analyst Stock Picks With Dividend Hikes Expected This Week
Summary: After years of a low interest rate environment, many investors have turned to equities not only for the growth potential but also for solid and dependable dividends, which help to provide an income stream.
- (2021-11-16 16:31) Ackman Axes Agilent Technologies in 3rd Quarter
Summary: Bill Ackman (Trades, Portfolio) has revealed his portfolio for the third quarter of 2021. The quarter saw Ackman sell out of his Agilent Technologies Inc. ( A , Financial) holding and make additions to his Chipotle Mexican Grill Inc. ( CMG , Financial), Domino's Pizza Inc. ( DPZ , Financial), Lowe's Companies Inc. ( LOW , Financial) and Hilton Worldwide Holdings Inc. ( HLT , Financial) positions.
- (2021-11-17 16:05) Agilent Increases Cash Dividend to 21 Cents Per Share
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent increases quarterly dividend to 21 cents per share.
- (2021-11-18 10:43) Agilent (A) to Report Q4 Earnings: What's in the Offing?
Summary: Agilent's (A) fiscal fourth-quarter results are expected to reflect portfolio strength and momentum across all segments.
- (2021-11-18 16:05) Dr. Otis Brawley Named to Agilent Board of Directors
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Dr. Otis Brawley, a leading authority on cancer research, has been named to the Agilent Board of Directors. | -7 | A | 2021-11-13 to 2021-11-26 |
### TASK
Predict the stock's 7-day forward return for A, rounded to the nearest integer percent.
Output only a single integer without a percent sign. Use a negative value for a loss, a positive value for a gain, and 0 for roughly flat.
### INPUT
[Symbol]: A
[Current Week]: 2021-11-20 to 2021-11-26
[Next Week]: 2021-11-26 to 2021-12-03
[Company Introduction]:
Agilent Technologies, Inc. (A) is a company in the Healthcare sector, operating in the Medical - Diagnostics & Research industry. It has been publicly traded since 1999-11-18. As of the latest data, its market capitalization is 41,969,403,213 USD. The stock trades on NYSE and is headquartered in US.
[Basic Financials]:
Financial ratios snapshot – last up to 4 quarters for A as of 2021-11-26:
Quarter ending 2021-10-31 (FY 2021 Q4, currency: USD):
- Profitability: net margin 26.6%, operating margin 23.8%.
- Valuation: P/E 26.9x, P/B 8.8x, P/S 28.7x, P/FCF 125.6x.
- Balance sheet & liquidity: debt/equity 0.51, debt/assets 0.25, current ratio 2.22, quick ratio 1.74, cash ratio 0.87.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 26.6%, FCF / OCF 85.9%.
Quarter ending 2021-07-31 (FY 2021 Q3, currency: USD):
- Profitability: net margin 16.6%, operating margin 21.2%.
- Valuation: P/E 44.0x, P/B 9.4x, P/S 29.3x, P/FCF 166.4x.
- Balance sheet & liquidity: debt/equity 0.58, debt/assets 0.27, current ratio 2.11, quick ratio 1.63, cash ratio 0.83.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 21.1%, FCF / OCF 83.5%.
Quarter ending 2021-04-30 (FY 2021 Q2, currency: USD):
- Profitability: net margin 14.2%, operating margin 18.9%.
- Valuation: P/E 47.0x, P/B 8.4x, P/S 26.6x, P/FCF 92.1x.
- Balance sheet & liquidity: debt/equity 0.61, debt/assets 0.28, current ratio 2.00, quick ratio 1.55, cash ratio 0.78.
- Efficiency & cash flow: asset turnover 0.15x, OCF / sales 31.0%, FCF / OCF 93.4%.
Quarter ending 2021-01-31 (FY 2021 Q1, currency: USD):
- Profitability: net margin 18.6%, operating margin 21.2%.
- Valuation: P/E 32.1x, P/B 7.7x, P/S 23.9x, P/FCF 187.7x.
- Balance sheet & liquidity: debt/equity 0.52, debt/assets 0.26, current ratio 2.06, quick ratio 1.62, cash ratio 0.79.
- Efficiency & cash flow: asset turnover 0.16x, OCF / sales 15.4%, FCF / OCF 82.8%.
[Earnings]:
Recent earnings (last up to 4 reports):
- 2021-11-22: EPS actual 1.21 / estimate 1.17 / surprise +0.04 | revenue actual 1660000000 / estimate 1461300000 / surprise +198700000
- 2021-08-17: EPS actual 1.10 / estimate 0.99 / surprise +0.11 | revenue actual 1586000000 / estimate 1659210000 / surprise -73210000
- 2021-05-25: EPS actual 0.97 / estimate 0.82 / surprise +0.15 | revenue actual 1525000000 / estimate 1745481927 / surprise -220481927
- 2021-02-16: EPS actual 1.06 / estimate 0.89 / surprise +0.17 | revenue actual 1548000000 / estimate 1461033707 / surprise +86966293
From 2021-11-20 to 2021-11-26, A's stock price decreased from 162.78 to 152.07. News during this period are listed below:
[News]:
- (2021-11-21 09:00) Dividend Increases: November 13-19, 2021
Summary: This weekly article series covers dividend changes. A summary table presents relevant data and key statistics of dividend increases.
- (2021-11-22 16:05) Agilent Reports Fourth-Quarter and Fiscal Year 2021 Financial Results
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent announces fiscal fourth quarter and full year financial results.
- (2021-11-22 21:05) Recap: Agilent Technologies Q4 Earnings
Summary: Agilent Technologies (NYSE:A) reported its Q4 earnings results on Monday, November 22, 2021 at 04:05 PM. Here's what investors need to know about the announcement.
- (2021-11-22 23:54) Agilent Technologies, Inc. (A) CEO Mike McMullen on Q4 2021 Results - Earnings Call Transcript
Summary: Agilent Technologies, Inc. (A) CEO Mike McMullen on Q4 2021 Results - Earnings Call Transcript
- (2021-11-23 14:34) Agilent's (A) Q4 Earnings & Revenues Beat Estimates, Rise Y/Y
Summary: Agilent Technologies' (A) fourth-quarter fiscal 2021 results reflect a solid end-market momentum and strong growth across Americas and China.
- (2021-11-23 15:00) Agilent to Present at Evercore ISI Virtual Healthcare Conference
Summary: SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent to present at Evercore ISI Virtual Healthcare Conference. | -2 | A | 2021-11-20 to 2021-12-03 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.